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Diurnal Variations in the Acute Response to Exercise in COPD 
Emilie Chan-Thim 
Purpose: Indices of lung function and symptoms have been shown to vary throughout 
the day. In COPD, these variations may have clinical repercussions. The general aim of 
this study was to investigate the impact of time of day on the acute response to exercise 
in individuals with COPD. Methods: Subjects followed a counterbalanced randomized 
design, performing three symptom-limited incremental cycling tests -each preceded by a 
pulmonary function test- at 08:00, 12:00, and 16:00. COPD medications were withdrawn 
6-24 hours prior to each test. Physiological response was measured breath by breath at 
rest and during exercise. Changes in outcomes were assessed with repeated-measures 
ANOVAs using the General Linear Model. Friedman tests were performed for non-
parametric data. Results: Fourteen subjects (9 men, 5 women) aged 71 ± 7 years with 
moderate airflow obstruction (FEV1: 58 ± 13% predicted) completed all evaluations. No 
overall time effect was found for peak exercise capacity (p= 0.22) or pulmonary function. 
However, changes at or beyond the suggested minimal clinically important difference 
were observed in nine of the 14 subjects for both variables. Resting RER was higher in 
the morning than at other time points (p = 0.001). Trends for time effects were found for 
mean VT (p = 0.096) and HR (p = 0.08). VT tended to decrease throughout the day, while 
HR tended to increase from morning to afternoon. Conclusion: These results suggest that 
diurnal variations in the acute response to exercise may be heterogeneous among COPD 
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1.0 Literature Review 
1.1 Definition 
The working definition of COPD, based on the widely recognized Global Initiative for 
Chronic Lung Disease (GOLD), is that it is a preventable and treatable disease with 
some significant extrapulmonary effects that may contribute to the severity in individual 
patients. Its pulmonary component is characterized by airflow limitation that is not fully 
reversible. The airflow limitation is usually progressive and associated with abnormal 
inflammatory response of the lung to noxious particles or gases [1]. 
The Canadian Thoracic Society broadly agrees with this definition; however, it has made 
a few adjustments. The Canadian Thoracic Society defines COPD as a respiratory 
disorder largely caused by smoking, and is characterized by progressive, partially 
reversible airway obstruction and lung hyperinflation, systemic manifestations, and 
increasing frequency and severity of exacerbations [2]. 
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Figure 1. COPD disease downward spiral. Adapted from la 













Poor quality of life
Isolation
1.2 Burden of Chronic Obstructive Pulmonary Disease 
COPD is a major cause of lung-related and all-cause mortality and disability [3-5] and is 
recognized as the fourth leading cause of death in Canada and worldwide [2, 3, 6]. The 
morbidity and mortality rates are projected to rise as the population ages and become the 
third leading cause of death worldwide by the year 2020 [2, 7]. The province of Quebec 
has the second highest COPD-related mortality rate in the country after the Northwest 
Territories [4]. The prevalence of COPD is markedly higher in current smokers and ex-
smokers as compared to non-smokers, in those over the age of 40 years, and is greater in 
men than in women [6]. The presentation of symptoms becomes apparent around the age 
of 55 years or greater [6, 8, 9]. The 
main symptoms of COPD are shortness 
of breath, cough, and sputum 
production [1, 2, 8, 10, 11]. Currently, 
the presentation of a chronic cough and 
sputum production which lasts for at 
least 3 months in each of 2 consecutive 
years is necessary for COPD diagnosis 
[1, 10] . Nonetheless, significant airflow limitation may develop without chronic cough 
and sputum production being present [1]. Therefore diagnoses may be made at any stage 
of the disease, yet patients often do not receive diagnosis until the presentation of COPD 
is well advanced [2, 8, 10]. This may account for the under reported diagnosis of this 
disease. The disease progression typically follows a downward spiral with the initial 
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presentation of chronic airflow limitation, to increasing inactivity, invalidity and poor 
quality of life (Figure 1).  
The socioeconomic burden of COPD is not without costs. In 2004-05, hospitalizations in 
relation to respiratory diseases were ranked as third, behind circulatory diseases and 
digestive disorders [5]; among respiratory diseases, COPD was ranked first [5]. Overall, 
respiratory diseases account for about 7% of total health care costs – or about $8.63 
billion – in Canada [5]. COPD is comprised of direct costs which include the diagnosis 
and medical management of the disease, in addition to indirect cost as a result of 
disability, absences from work, the expense for a caregiver and premature death [1]. As 
the disease progresses there exists a direct relationship with the financial burden on the 
health care system as patients require more direct care, in terms of hospitalizations and 
oxygen (O2) therapy [1, 12].
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1.3 Risk Factors for COPD 
1.3.1 Tobacco smoking 
The most commonly associated risk factor for COPD is smoking [1]. In 80 to 90% of 
cases, cigarette smoking is believed to be responsible for the development of COPD [4]. 
Exposure to tobacco smoke has a cumulative effect over time, progressively increasing 
the risk of developing COPD [1]. Smoking cessation is the most successful intervention 
to reduce the risk of developing COPD and in slowing down the disease progression in 
individuals with COPD [13, 14].    
Important factors to consider in risk assessment are the age when the individual started 
smoking, total consumption of tobacco smoking which can be calculated in pack years 
(the number of packs smoked per day multiplied by the number of years smoked), and 
current smoking status [1, 10].  Risk has been demonstrated to be dose related in current 
smokers [15]. Yet there is no defining amount, in terms of tobacco consumption, where 
increased risk for COPD occurs [1]. Not all smokers develop COPD which suggest that 
other factors may play a contributing role.  
1.3.2 Genetics 
When comparing two individuals with the same smoking history, one may be diagnosed 
with COPD while the other may not [1]. This may be due to a genetic predisposition and 
what is known as the gene-environment interaction [1]. In certain cases, individuals who 
have never smoked may still end up with COPD [1]. Indeed, a rare hereditary deficiency 
in alpha-1-antitrypsin greatly increases the risk for an individual to develop COPD [2, 6, 
8, 10]. Alpha-1-antitrypsin is a major inhibitor of serine proteinases; when unchecked, 
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proteolysis may occur and lead to lung tissue damage [16]. In the COPD population, 
alpha-1-antitrypsin deficiency is present in only about 1-2% of cases [7]. However, in 
individuals with COPD who are less than 40 years of age, 50% of cases are likely 
attributed to alpha-1-antitrypsin deficiency [7]. In addition, if these genetically 
susceptible individuals are smokers, it has been demonstrated that they may have an 
accelerated lung function decline [10]. 
1.3.3 Occupational exposure  
According to the American Thoracic Society, occupational exposure accounts for 
approximately 15% of the burden of COPD [17]. Long-term exposure to occupational 
dusts, chemical fumes or agents increases the risk of developing COPD, independent of 
smoking habits [1, 10, 18]. When inhaled, these noxious particles have been shown to 
cause an inflammatory response in the lungs [8]. Repeated exposure to these particles 
increases the lung function decline and may increase the risk of respiratory exacerbations 
(a worsening of respiratory symptoms) in those who already suffer from COPD [10].   
1.3.4 Air pollution 
In developing countries, indoor air pollution carries a heavy burden. It is estimated that 
over two million women and children are killed each year from exposure to biomass fuel 
and from exposure to wood burning stoves [1]. Biomass fuels, coal, wood, and dung are 
used in open fireplaces and in stoves in developing countries as a means for cooking and 
heating [1].  Indoor air pollution represents an important risk factor in the development of 
COPD and the numbers, especially in women, continue to grow [1]. 
6 
 
In urban areas, the impact of outdoor sources of air pollution in COPD remains unclear 
[1]. It is thought that the role of air pollution is small in COPD in comparison to the risk 
associated with cigarette smoking [10]. Part of the problem is that sources of outdoor air 
pollution are difficult to pinpoint to a single culprit and in trying to identify the long-term 
effects of exposure to individual pollutants [1].  However, research has demonstrated that 
fossil fuel combustion and motor emissions have been associated with decreased 
respiratory function [19]. Indeed, outdoor air pollution has been shown to be harmful in 
those individuals with existing heart and lung disease [1].  
1.3.5 Lung growth and development  
New concepts are emerging looking at the role of early lung development on future 
susceptibility to develop adult-onset chronic respiratory diseases, such as COPD [20].  It 
has been hypothesized that COPD may have origins stemming from as early as the fetal 
stage of life, since bronchial tree development is known to occur by the 16
th
 week of 
gestation [21].  Factors which may adversely impact lung development and subsequent 
lung function include early environmental factors such as exposure to intrauterine smoke, 
maternal health and nutrition, childhood exposure to pollutants, exposure to 
corticosteroids, prematurity, exposure to O2, imbalance in growth factors, abnormal 
signaling or injury to capillary vascularization [20, 22]. Alveolar development may 
continue up until the age of seven years, and it is believed that maximal lung function is 
reached by early adulthood [20, 22]. Poor lung growth has been associated with a 
decreased forced expiratory volume in 1 second (FEV1) in adulthood [22]. 
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Another approach to investigating this late-onset disease is to determine the intrinsic 
effect of aging on COPD [22]. Yet, the challenge to this type of studies is how to 
determine the natural history of aging in addition to the amount of time required to make 
such observations[22]. Research has focused on determining the relationship with 
extrinsic factors and aging and what has been demonstrated is that a young lung does not 
react to a given stimulus in the same manner as an older lung [22]. For example, an older 
lung may demonstrate a greater effect from smoking than a younger lung [22]. In an older 
active smoker with more severe airway obstruction, the rate of decline in lung function 
may not normalize upon smoking cessation [22, 23]. A contributing factor may be 
associated with the immune response which has been shown to begin to decline by the 
age of 50 years [24]. Therefore, the aging process, under the influence of extrinsic 
factors, may increase the risk of an individual to develop COPD yet it does not mean an 
individual will result in COPD [22]. 
1.3.6. Infections 
Infections, both viral and bacterial in origin, may increase the risk of developing COPD 
and the risk of having a COPD exacerbation [25, 26]. A healthy human airway is sterile, 
yet in COPD, the immune response becomes compromised and cannot respond to 
infections adequately [26]. In the case of a viral infection, the lung epithelial cells 
demonstrate an amplified inflammatory response [25]. With bacterial infections, the 
microbial pathogens have a propensity to invade the lower airways and result in the 




Increased risk of infections has been suggested to be linked to low birth weight [18]. An 
infant with a low birth weight has an increased probability of being hospitalized for 
respiratory tract infections [18, 27]. Repeated childhood respiratory tract infections may 
be indicators of the future onset of respiratory complications, such as decreased lung 
function in adulthood and an increased presentation of respiratory symptoms [2, 8, 10, 
18]. An important component in COPD is the lungs’ ability to respond to an insult. 
Infection has been shown to accelerate the presentation of COPD [18]. 
1.3.7. Oxidative stress 
The lungs are naturally exposed to oxidants through processes such as phagocytocis, 
however further exposure may result from external sources such as pollutants and 
cigarette smoke [28].  When the balance between oxidants and anti-oxidants shifts away 
from the protective effects of antioxidants, this is known as oxidative stress [28]. This 
may occur in the presence of excess oxidants or through the depletion of antioxidants 
[28]. 
As a result of smoking, an excessive oxidative burden is placed on the lungs [28]. For 
example, inflammatory leukocytes have been shown to migrate to the lungs and release 
O2 radicals [28]. Meanwhile, smoking has also been shown to reduce the amount of 
plasma antioxidants, a response which is also observed under conditions of acute 
exacerbation in COPD [28]. This oxidative stress triggers a plethora of additional 
responses, critical in COPD, such as the inactivation of antiproteases, mucus 
hypersecretion, airspace injury, increased influx of neutrophils into the lungs, 
transcription factor activation and gene expression of pro-inflammatory mediators [28]. It 
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1.4 Pathology, Pathogenesis and Pathophysiology of COPD 
1.4.1 Pathology  
The two most common underlying disease processes that lead to COPD are emphysema 
and chronic bronchitis [4, 10]. Chronic bronchitis is described by small airway disease, 
where chronic inflammation causes structural changes resulting in narrowing of the small 
airways [6]. Emphysema is described by the destruction of the gas-exchanging surfaces 
of the lungs (i.e. the alveoli) [10]. In essence, COPD is a heterogeneous disorder by 
nature, characterized by the dysfunction of the small and large airways, as well as by the 
destruction of the lung parenchyma and its vasculature, which can be represented in 
highly variable combinations [11]. Developing insidiously over time, COPD is viewed as 
a preventable and treatable disease [2, 6]. 
1.4.2 Pathogenesis  
    1.4.2.1 Inflammatory response 
In COPD, the inflammatory mechanisms underlying this disease are not fully understood, 
yet an amplification of the normal inflammatory response is thought to occur [1, 29]. The 
inflammatory response is initiated after chronic exposure to irritants such as cigarette 
smoke or inhaled toxic particles or gases [1, 29]. In certain individuals, genetic 
determinants may increase an individual’s susceptibility to an amplified immune 
response [29, 30]. The amplified immune response may persist even after smoking 
cessation as tissue damaged through a history of smoking is not simply repaired upon 
smoking cessation [30]. 
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Obstruction is thought to originate in the small airways and progresses to the gas-
exchanging surfaces [31, 32]. The airway epithelium is the first line of defense against 
toxic inhalants [33].  Damage to the airways initiates the innate and adaptive 
inflammatory immune responses [31]. The innate immune response reacts quickly in an 
unspecified manner to inflammation however, it does not retain any memory of the event 
to assist with any future re-occurrences [31]. Meanwhile, the adaptive immune response 
transpires at a much slower pace, yet retains memory of prior insults and expresses 
greater specificity to those pathogens or nefarious agents [29, 34]. 
 The role of the innate host defense is to enhance mucus production and clearance and 
maintain the epithelial barrier [31, 35]. Additionally, the innate host defense leads to the 
exudation of plasma proteins into all regions of the airways [29, 36]. The inflammatory 
immune response instigates a response where there is an influx of inflammatory cells into 
the airway lumen and in the airway walls, including neutrophils, macrophages and T 
lymphocytes (both CD+4 and CD+8) [37].  These cells then release inflammatory 
mediators such as chemotactic factors, proinflammatory cytokines and growth factors 
[18]. This response is meant to clear the lungs and resolve inflammation however, in 
COPD this reaction also contributes to the worsening of the disease as the repair process 
is altered and tissue dysfunction is the result [34, 36]. The extent to which the airway 
lumen is filled with inflammatory and mucus exudates, reflects the severity of the repair 
and remodeling process [31]. 
An accumulation of dendritic cells in the epithelium is important as it provides a link 
between the innate and adaptive immune response [29]. The dendritic cells may initiate 
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the adaptive immune response presenting antigen to T and B lymphocytes [29]. A signal 
is initiated where antibody-producing plasma cells or memory cells are formed, yet in 
COPD this process is not clearly understood and it has been proposed that antigens may 
be derived from inert or even infectious particles detrimentally affecting the immunes 
response [29].  
In conjunction with infiltration in the alveolar wall by the innate and adaptive 
inflammatory immune response, an accumulation of fibrotic tissue can cause thickening 
of the alveolar wall [31, 36]. Transforming growth factor-beta (TGF-β), is an influential 
mediator in the immune response and can stimulate the fibroblast matrix and resultant 
fibrosis [36].  Under normal repair processes the lung architecture is preserved [36]. Yet 
in COPD, the lungs repair response and remodeling response initiate changes to the lung 
tissues such that the airway walls thicken and obstruct the lumen of the conducting 
airways [1, 33]. It has been hypothesized that airway inflammation may be responsible 
for changes in the structure and contractility of airway smooth muscles [38]. Moreover, 
increased smooth muscle in addition to thickened airway walls and mucus accumulation 
may contribute to airway narrowing and occlusion in COPD [39]. Yet the interaction 
between inflammatory cells and smooth muscles cells is not fully understood and requires 
further research [38].  
1.4.2.2 Protease-antiprotease imbalance 
Proteases may be derived from inflammatory and epithelial cells and may be found in 
excess amounts in COPD [1]. Proteases breakdown connective tissue components such as 
elastin in the lungs, meanwhile antiproteases protect against this effect [1, 8]. Yet in 
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COPD, an imbalance exists between proteases and antiproteases where an increase in 
proteases leads to the weakening of the parenchyma walls, which is characteristic of 
emphysema [1]. 
1.4.3. Pathophysiology 
1.4.3.1 Expiratory flow limitation and hyperinflation 
COPD is a respiratory disease, yet to gain a full scope of what is occurring during 
respiration, a brief overview of the lung volumes and capacities needs to be addressed. 
The lung can be broken down to four lung volumes and four capacities. When we inspire 
and expire under normal conditions, this is known as the tidal volume (VT) [40]. Yet, we 
have the ability to take a larger breath in, tapping into our inspiratory reserve volume 
(IRV) should the need be required [40]. We can additionally tap into our expiratory 
reserve volume (ERV) and exhale beyond our usual VT [40]. Yet even when trying to 
exhale maximally, air remains trapped in our lungs and this is called the residual volume 
(RV) [40]. The total lung capacity (TLC) is the measure of all four lung volumes [40]. 
The point where the lungs are at basal level of inflation is termed as the functional 
residual capacity (FRC) or end-expiratory lung volume (EELV) [40]. Other respiratory 
capacities may be measured using spirometry measurements [40]. At the end of a normal 
exhale, a maximal intake of breath is known as the inspiratory capacity (IC) [40]. A 
complete maximal inhale and maximal exhale is a measure of vital capacity (VC) [40]. 




Figure 2 – Lung volume measurements.  
TLC = total lung capacity (IRV+VT+ERV+RV), VC = vital capacity (IRV+VT+ERV),  
IC = inspiratory capacity (IRV+VT), FRC = functional residual capacity (ERV+RV), 
IRV= inspiratory reserve volume, VT = tidal volume, ERV = end respiratory reserve 
volume, RV = residual volume [40]. 
Spirometry is a physiological test which is used to detect the presence of airflow 
limitation by measuring the flow or volume of air inhaled and exhaled over a specified 
amount of time [41]. Forced vital capacity (FVC) and FEV1 are the two most important 
measures to assess COPD airflow limitation [41]. Indeed, airflow limitation is the 
standard by which COPD classification and progression are determined [18]. The stages 
of COPD severity is based on the Global Initiative for Chronic Obstructive Pulmonary 
Disease (GOLD), as shown in Table 1 [18].  
FVC is measured from a full inspiration and corresponds to the volume expired forcefully 
and completely, while FEV1 is the volume delivered within the first initial second of the 
FVC maneuver [41]. Airflow limitation is typically characterized by an accelerated 
decline in FEV1 and/or a decreased ratio of FEV1 over FVC [10, 40]. The decreased 
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FEV1 and FEV1/FVC ratio primarily result from the extent of inflammation, fibrosis and 
narrowing of the peripheral airway [18].  Peripheral airways, when obstructed, 
progressively trap air during expiration, resulting in hyperinflation [18]. With 
emphysema, the destruction of air sacs can be observed, enlarging the air space within the 
lungs causing additional air trapping. Air trapping can occur as the weakened structure 
collapses on expiration and traps air within the lungs, leading to hyperinflation of the 
lungs [40]. The hyperinflation may further decrease the FEV1 and FEV1 to FVC ratio 
[42].  
Table 1 - Spirometric Classification of COPD Severity Based on Post-Bronchodilator 
FEV1 
 
Stage Severity Airflow limitation criteria 
I Mild FEV1/FVC < 0.70 
FEV1 ≥ 80% predicted 
II Moderate FEV1/FVC < 0.70 
50% ≤ FEV1 < 80% predicted 
III Severe FEV1/FVC < 0.70 
30% ≤ FEV1 < 50% predicted 
IV 
Very Severe FEV1/FVC < 0.70 
FEV1 < 30% predicted or FEV1< 50% predicted plus chronic 
respiratory failure 
FEV1: forced expiratory volume in one second; FVC: forced vital capacity; respiratory failure: arterial 
partial pressure of oxygen (PaO2) less than 8.0 kPa (60 mmHg) with or without arterial partial pressure of 
CO2 (PaCO2) greater than 6.7 kPa(50 mmHg) while breathing air at sea level. Adapted from Global 
Initiative for Chronic Obstructive Pulmonary Disease, Updated 2009 [18]. 
 
Hyperinflation can be qualified as either static or dynamic or in a combination of both. 
Static hyperinflation is caused by a decrease in elasticity of the lung parenchyma [40]. 
Dynamic hyperinflation is more common and may occur independent of or in addition to 
static hyperinflation [40]. Dynamic hyperinflation stems from air being trapped within 
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the lungs after each breath when inhalation is instigated before full exhalation has been 
achieved, creating a disequilibrium between the volumes inhaled and exhaled [40]. 
Therefore, air trapping is perpetuated with each successive breath [40]. Dynamic 
hyperinflation may occur without prejudice at any stage of COPD [40]. The ability to 
exhale depends on the degree of airflow limitation and the time available for exhalation 
[40]. Therefore, dynamic hyperinflation often occurs in situations associated with 
increased ventilation, such as during physical activity, and during exacerbations of COPD 
[40]. 
Lung volumes are measures which best correspond with the presentation of symptoms 
and impairment of functional capabilities [40].  When the VT during exercise encroaches 
on the TLC envelope, further volume expansion is impossible [11].  The IC is often used 
to indirectly measure hyperinflation during repeated exercise tests in COPD [41, 43]. The 
IC maneuver tracks the changes in EELV in hyperinflation [43].  
1.4.3.2 Mucus hypersecretion 
Mucus production occurs in the lining of the airway epithelium and is caused by 
bronchial glands and by goblet cell secretions [33]. Chronic stimulation by toxic particles 
induces a dysregulation in the mucus response where more mucus is produced through 
goblet cell metaplasia and, when mucus clearance is unable to keep up with this increased 
production, this can lead to a buildup of mucus in the airway lumen [29]. Additionally, 
secretions can detrimentally compromise the airway surface tension causing airway 
instability, increasing the risk of airway closure and mucus obstruction [44]. Further 
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disruption in the epithelial barrier can occur, allowing the infiltration of damaged tissue 
[29]. Infiltrates include macrophages, CD8+, CD4+, T lymphocytes and B cells [29]. 
1.4.3.3 Gas exchange limitations  
Under everyday conditions, healthy individuals are rarely limited by their ventilatory 
capacity. Healthy individuals can adapt to increases in demand on the respiratory system 
to meet the increased O2 demand and carbon dioxide (CO2) production [45]. However, in 
chronic lung diseases, several factors impede gas exchanging properties. Gas exchange is 
initiated at the level of the alveoli within the lungs, where the distribution of O2 through 
the vascular bed is known as gas perfusion [46]. Gas perfusion is not uniform across the 
lungs as the lungs are made up of many compartments and each compartment may have 
different ventilation to perfusion ratios (V/Q) [46]. In COPD, a broad range in V/Q 
distributions can be expected as both ventilation and the distribution to blood flow may 
be altered [46]. The different V/Q ratio’s can range from 0, for example in the case of a 
shunt were venous blood returns to the heart bypassing the gas-exchanging surfaces, to 
infinite, when there is ventilation to an area of the lungs where there is no blood flow 
[46].  The more uniform the distribution, with a mean value approaching 1.0 signifies a 
better gas exchange capacity [47, 48]. However, a reduction in the V/Q can lead to an 
increase in CO2 circulating in the blood and this is known as hypercapnea [18, 45]. 
Increased CO2 in the circulating blood is known to decrease the blood pH [49]. 
Furthermore, evidence of increased lactic acid production in COPD patients has been 
demonstrated to increase ventilation as well as forecast greater muscle fatigue [3]. 
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Ventilatory limitation can also occur under conditions of increased workload placed on 
the respiratory system, which can result from increased airway resistance, respiratory 
muscle dysfunction or increased risk of hyperinflation, tipping the balance between load 
and respiratory capacity [45]. This, in turn, can lead to hypoxemia, which is a decrease in 
the partial pressure of oxygen (PO2) available in the circulation [18]. Hypoxemia is 
measured through arterial PO2 (PO2 below 55 mmHg) or by pulse oxymetry (SpO2 
<85%) [18, 45]. Yet, the most common cause of hypoxemia has been identified to be due 
to ventilation-perfusion mismatch [46]. 
Further limitations to gas-exchange and perfusion can occur in the emphysematous 
patient, as structural changes to the parenchymal wall results in damage to the alveoli and 
the alveolar-capillary interface [18, 45]. Therefore, a smaller surface area is available for 
gas-exchange [46].  
In summary, gas exchange limitation occurs in COPD with the decrease in available O2 
and increase in the circulating CO2.  The exchange in gases deteriorates with the 
progression of the disease. The poor V/Q may be used as an indicator of increasing 
emphysema severity [18]. 
1.4.3.4 Respiratory muscle dysfunction 
In normal lungs, EELV is the point at which the respiratory muscles are at rest and a 
balance is achieved between the counter pressures of the chest wall and of the lungs [40]. 
In COPD, destruction of elastic tissues alters the lung recoil pressure shifting the balance 
between counter pressures [40]. A greater FRC results, contributing to lung 
hyperinflation as air remains trapped within the lungs and places the respiratory muscles 
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in a mechanically disadvantageous position [40, 50, 51]. The diaphragm is the main 
generator of tidal breathing [52]. When the optimal diaphragm length-tension relationship 
has been compromised, this requires that a greater respiratory force be exerted during 
tidal breathing [53]. Initially the diaphragm can adapt to the overload and generate 
greater force [51]. The diaphragm demonstrates adaptations to resist fatigue by increase 
the proportion of slow, fatigue-resistant fiber types [52, 54]. Additionally, adaptations to 
myofibril sarcomere length have been demonstrated, adapting to work at a shortened 
length increasing muscle fatigue resistance [55]. Yet with time the respiratory muscle 
strength and endurance are compromised in COPD due to the increasing load placed on 
them [51]. As a consequence of reduce respiratory muscle strength, hypercapnea, 
dyspnea, nocturnal O2 desaturation and poor exercise tolerance are evidenced [50]. 
1.4.3.5 Peripheral muscle dysfunction 
It has been postulated that skeletal muscle dysfunction in chronic respiratory disease may 
be associated to a number of pathophysiological abnormalities, namely to sedentary 
lifestyle deconditioning, systemic inflammation, oxidative stress, blood gas disturbances, 
corticosteroid use, malnutrition, and reductions in muscle mass [50]. Lower limb 
ambulatory muscles have been most commonly studied [50]. The generalizability of these 
findings to other peripheral muscles is, as yet, unclear [50].   
Unlike respiratory muscles which demonstrate adaptations similar to an endurance 
trained athlete, the skeletal muscles demonstrate atrophy and consequently there is a 
reduction in aerobic capacity [56]. Currently, these findings point to peripheral muscle 
adaptations instigated by deconditioning and a switch in fiber typing toward more 
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fatigable fibers [54, 56]. The proportion of slow twitch fibers is decreased and the 
proportion of fast-twitch fibers is increased [50, 54, 56]. The resultant reduction in 
aerobic capacity entrains an increase in lactic acidosis production for a given work rate in 
COPD and subsequent increases in minute ventilation (VE) [57]. 
1.4.3.6 Exercise intolerance in COPD  
Until recently, ventilatory limitation was thought to be the only limiting factor to exercise 
capacity in COPD patients [45]. However, it has been shown that with comparable 
ventilatory capacities, there exists a wide range in the exercise tolerances attained in a 
COPD patient population [58]. Therefore, the mechanisms involved in exercise 
intolerance in patients with COPD are actually much more complex and suggest the 
involvement of several systems [45, 53]. Moreover, poor exercise tolerance has been 
closely related to impairment and disability in COPD and is a better predictor of poor 
quality of life and subsequent survival than are spirometry measures alone or the need for 
O2 therapy [42, 59]. 
Studies have been conducted to investigate the two most commonly reported symptoms 
related to exercise cessation, namely leg fatigue and dyspnea [3, 60, 61]. The onset of 
dyspnea may be related to ventilatory limitations, the increased work of breathing, 
hyperinflation and/or gas exchange limitations [3, 40]. To relieve the sensation of 
dyspnea, VE and respiratory rate (RR) increase [62]. However, as RR increases, 
expiratory time is further decreased and a vicious cycle of gas trapping and progressive 
dynamic hyperinflation occurs [40]. As a result of gas trapping in the lungs, individuals 
with COPD respire at a much higher EELV and this is termed static lung hyperinflation 
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[63]. The TLC does not change, even under conditions of exercise, and an IC maneuver is 
an indirect measure of the changes to the EELV or the scope of hyperinflation [64]. 
Under exercise conditions, individuals with COPD become physiologically limited by the 
maximal TLC envelope and, during exertion, it forces premature exercise termination as 
they are unable to keep up with the body’s demand for O2 [58].  Drugs exist which can 
deflate the lungs, and permits a greater IRV such as bronchodilators which relax the 
airway smooth muscle and improve expiratory flow rates reducing dyspnea and 
improving exercise tolerance [2].  
The effectiveness of respiratory medications are significant in terms of improving 
ventilation, yet the effects are limited in patients with a greater susceptibility to leg 
fatigue during exercise tolerance testing [61, 65, 66].  Despite similar improvements to 
expiratory flow it is the muscle fatigue which limits performance, hypotheses have been 
proposed to try and elucidate the mechanism behind muscle fatigue in COPD [66, 67]. 
Muscle fatigue in COPD has been linked to peripheral muscle impairments, such as poor 
oxidative capacity, muscle atrophy and muscle weakness [66]. An increased 
susceptibility to contractile fatigue and increased lactate accumulation as well as early 
muscle acidosis may also have contributing roles [66, 67]. Additionally, the type of 
exercise modality (eg. walking versus cycling) has been shown to influence symptom 
perception (eg. dyspnea and leg fatigue, respectively) [61, 65, 66].  In these patients, 
treatment of the peripheral muscles in combination with pharmacological interventions 




1.4.3.7 Pulmonary complications  
Pulmonary hypertension frequently develops further on in the progression of COPD [18, 
68]. Pulmonary hypertension is the result of small pulmonary arteries constricting in 
response to reduced levels of O2 in the circulation [18]. The arterial constriction increases 
the resistance to blood flow and increases the work required for the heart to pump 
through the pulmonary circulation [68]. The pulmonary arterial constriction has been 
shown to induce structural changes in the intimal thickness (hyperplasia) and smooth 
muscle hypertrophy [18, 68]. The presence of pulmonary hypertension has been 
associated with shorter survival and worst clinical outcomes [68]. Pulmonary 
hypertension may lead to right ventricle hypertrophy and cardiac failure or cor pulmonale 
[18]. 
Further pulmonary complications result from transitory changes such as during a 
respiratory exacerbation. An exacerbation is perceived as the amplification of subjective 
respiratory symptoms; dyspnea, cough and sputum production [8, 69]. Exacerbations are 
associated with physiological deterioration resulting in poor expiratory flow, increased 
dyspnea, and increased inflammatory markers [69, 70]. It is believed that as many as 50% 
of episodes of exacerbations go unreported, the median reported exacerbations ranging 
between 2.5 and 3 episodes per year [71]. Exacerbations may be triggered by bacterial or 
viral infections or environmental pollutants [18, 70]. Relief from exacerbation symptoms 
takes a median of seven days, whereas recovery of peak flow may range from 6 to 35 
days and, in a significant number of patients, approximately 7% do not return to prior 
baseline lung function values [72]. It has been hypothesized that the incomplete return to 
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initial baseline lung function after an exacerbation may contribute to the disease 
progression and decline in lung function [70].  Treatments with oral corticosteroids have 
been documented to improve the rate of recovery from an exacerbation [73-75]. 
Antibiotics are the preferred pharmacotherapy treatment when changes in sputum are 
present [70]. 
1.4.3.8 Comorbid conditions  
COPD has been linked to multiple comorbid conditions including ischemic heart disease, 
osteopenia or osteoporosis, glaucoma, cataracts, cachexia, sleep-related disorders, anxiety 
and depression [2, 18]. As COPD presents itself in an older population, comorbidities are 
quite common and may be as a result of the aging process or of COPD [18]. Currently, 
specific guidelines for the management of such comorbidities do not exist and therefore 
are managed on an individual basis [18]. 
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Figure 3. A comprehensive approach to the management of chronic obstructive pulmonary disease (COPD). 
AECOPD Acute exacerbation of COPD; LABA Long-acting beta2-agonist; MRC Medical Research Council; PRN 
As needed; Rx Treatment. Can Resp J 2008; 15 (Suppl A): 1A-8A. 
 
1.5. Management of COPD  
There is no known cure for COPD [6, 8]. However, modern management of the disease 
does allow for a deceleration in the progression of the disease. The goal of COPD 
management, as stated by the Canadian Thoracic Society, includes prevention of disease 
progression; reduction of the frequency and severity of exacerbations; alleviation of 
dyspnea and other respiratory symptoms; improvement of exercise tolerance; prompt 
treatment of exacerbations and complications of the disease; improvement of health 
status; and reduction of mortality [2]. This can be achieved through a stepwise approach 
(Figure 3) [2].   
The management and assessment of COPD are done on an individual basis and should 
include a thorough medical evaluation, patient history as well as a physical examination 
[2]. The single most effective intervention to reduce the risk of developing COPD, or to 
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slow down the progression of the disease, is through smoking cessation [2].  
In the management of COPD, pharmacotherapy comprises an integral role. Due to the 
progressive nature of COPD, the pharmacological treatments tend to be cumulative over 
time [1]. Furthermore, the number and frequency of exacerbations, comorbidities and 
other complications may influence the course of pharmacological treatment [1, 2]. 
However, pharmacotherapy has its limitations such that it has been unable to demonstrate 
an improvement in the progressive decline in pulmonary function [76].  
Changes achieved through pharmacological intervention may be reflected in changes in 
FEV1 and improvements in lung volumes which help alleviate symptoms of dyspnea [8]. 
Bronchodilators are prescribed first of which there are three types, namely beta agonists, 
anticholinergics and methylxanthines [8]. β2-agonist, such as salbutamol, salmeterol, 
formoterol and terbutaline, relax airway smooth muscle by stimulating the β2-adrenergic 
receptors, increasing cyclic adenosine monophosphate(cAMP) and producing antagonist 
bronchoconstriction [1]. Anticholinergics such as ipatropium bromide, oxibromide and 
tiotropium bromide block the acetycholine effect and increases the bronchodilating 
duration [18]. Methylxanthines’ role in COPD pharmacotherapy remains controversial. 
Methylxanthines, such as theophyllines and aminophyllines, have a bronchodilating 
effect, display anti-inflammatory properties, control blood plasma levels and have been 
reported to reduce exacerbations in COPD [8, 77]. However, this medication has a risk of 
toxicity [1]. Methylxanthines are a nonselective phosphodiesterase inhibitor, which can 
be cumulative in the system as with age a decreased clearance of the drug has been seen 
[1]. Therefore, there is an increase in adverse events in using this medication, from a risk 
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of overdose, to cardiovascular or neurological dysfunction to less severe effects including 
headaches or nausea etc. [1, 2]. Overall changes seen in methylxanthines only 
demonstrate modest improvements in pulmonary function, exercise capacity and dyspnea 
[2]. 
Bronchodilators can be further dichotomized into short and long-acting categories. Short-
acting bronchodilators, which include anticholinergics and β2-agonists, are used to 
improve pulmonary function, dyspnea and exercise capacity [2, 78]. The benefits 
however are inconsistent [2]. Long-acting bronchodilators, such as long-acting β2-agonist 
(LABA), provide more sustained benefits in pulmonary function, dyspnea and health 
status in moderate to severe disease [2]. However, side effects include risk of 
palpitations, tachychardia, irritation, insomnia, muscle cramps and tremors [2]. Long-
acting anticholinergics (LAACs) used in moderate and severe disease have greater 
sustained effects on pulmonary function, dyspnea and health status [2]. Few side effects, 
such as dry mouth and on rare occasion’s arrthymias, have been associated with LAACs, 
but in general they are well tolerated [2]. Furthermore, there are combination drugs of 
long-acting bronchodilators, LAACs and LABAs, such as salbutamol/ipatropium, 
providing complimentary benefits in moderate and severe disease and exhibit greater 
consistency in health status and fewer exacerbations [1, 2, 8].  
Glucocorticoids affect the inflammatory cascade [8]. Inhaled corticosteroids (ICS), such 
as fluticasone, budesonide and beclometasone dipropionate, act as stand-alone drugs and 
are a controversial method of treatment in COPD as they demonstrate inconsistent results 
[1, 2]. ICS aim to improve airway inflammation, pulmonary function, symptoms 
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presentation, decrease the number of exacerbations and improve health status [2, 18]. 
Chronic use of ICS may result in reduced bone density, repeated bouts of pneumonia, 
cataracts and glaucoma [2]. Side effects may include dysphonia (impairment of the 
voice), oral candiasis (thrush or fungal infection) and ecchymosis (bruise) of the skin [2]. 
Therefore, combination therapy has been used where pharmacological agents from two 
different classes have been combined, such as long-acting bronchodilators and inhaled 
corticosteroids (ICS/LABA), like with  fluticasone/salmeterol and budesonide/fomoterol 
[1, 2, 8]. ICS/LABA have demonstrated greater consistency above what is found 
individually in moderate and severe disease on pulmonary function and exercise capacity 
and improves the occurrence of exacerbations, pulmonary function and health status [2, 
8].  
Oral corticosteroids, like prednisone or prednisolone, carry higher risks of adverse side 
effects such as adrenal suppression, osteoporosis, cataracts, diabetes, skin thinning, 
muscle weakness, hypertension and psychosis [1, 2]. However, this mode of treatment 
has been shown to increase FEV1 in a subset of the COPD patient population [2]. Overall, 
sustained use of this medication is not recommended [2].  
Selection of pharmacotherapy may also be in part due to cost and convenience [18]. It is 
easier to take one medication versus two, ergo combinations of medications. As the 
disease severity increases, it becomes more effective to take a long-acting medication as 
compared to short-acting interventions, which would need to be taken at increasing 
frequencies [18]. As well, the chronic treatment of glucocorticosteroids is to be 
discouraged as they may have a toxic effect [18]. 
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Other interventions include vaccines, alpha-antitrypsin augmentation therapy, antibiotics 
used in the treatment of infections and during exacerbations, mucolytics agents as an 
alternative to glucocorticosteroids, yet research has shown little benefit and do not widely 
recommended mucolytics, antioxidants agents, immunoregulators, vasodilators and 
others [2, 18]. 
Education is crucial for self-management, in the instruction of proper use of inhalers and 
O2 if necessary, in aiding in early recognition of signs of exacerbation, and in end-of-life 
issues [2]. Other non-pharmacological interventions exist, namely pulmonary 
rehabilitation and, if needed, O2 therapy and/or surgical intervention [2]. 
Pulmonary rehabilitation is a multidisciplinary intervention combining exercise training, 
education, nutritional intervention and psychosocial support and has gained widespread 
support in the management of systemic consequences of COPD [2, 18, 50, 79]. 
Pulmonary rehabilitation promotes lifelong management and has been shown to 
significantly reduce symptoms of dyspnea and to increase exercise tolerance and health 
related quality of life as compared to standard of care alone in COPD patients [50, 80]. 
Exercise training is considered the key component as it is responsible for many of the 
benefits associated in pulmonary rehabilitation [2, 50, 79]. Exercise training can improve 
muscle function, improve cardiovascular function, decrease symptoms, reduce mood 
disturbances, and improve cognition [50, 80-83]. Physiological adaptations which occur 
with exercise training include increased peak oxygen consumption (VO2peak), greater peak 
work rate or endurance time to constant-load exercise, reduced VE for a given workload, 
and improvements in the oxidative capacity [57, 81, 84]. However, the optimal exercise 
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training dose (intensity, duration and frequency) has yet to be determined to elicit the 
most benefits [50, 80]. 
As COPD progresses, O2 therapy may initially be needed to assist during exercise 
training, so as to delay ventilatory limitation and/or exercise-induced O2 desaturation. It 
may also be needed at night only, to prevent nocturnal hypoxemia. Eventually, in cases of 
severe resting daytime hypoxemia, continuous O2 supplementation may be used, 
potentially increasing survival in these patients [2, 50]. 
In individuals afflicted with severe COPD surgery may be required either through lung-
volume reduction or lung transplantation [85]. Lung transplantation is a more limited 
option as it is accompanied by increased risks of complications which may impair 
survival [86]. Pulmonary rehabilitation is recommended before and after surgery to help 
bolster prospective outcomes [87]. Transplantation is usually only considered when FEV1 
is < 25% of predicted values [86]. Lung-volume reduction surgery improves static lung-
recoil, respiratory muscle function, increases lung function and decreases hyperinflation 
[40, 85]. The improvements from the reduction surgery are preserved over the long-term 
unlike exercise training or pharmacological interventions which are only effective so long 
as they are being practiced [86]. However, future research is aimed at determining if the 
pharmacological use of tiotropium could be used with sufficient magnitude so as to 
mimic the effects of lung-volume reduction. Pharmacotherapy could then potentially 
eliminate the need for surgery, which is a much more invasive procedure [40]. 
In summary, optimal management is desired to prevent or reduce the disease progression, 
decrease the number, frequency and severity of exacerbations, alleviate symptoms, and 
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increase activity levels and quality of life [2]. Current management is achieving this, yet 
further research is needed. Suggestions have been made to investigate the link between 
airflow limitation and smooth muscle constriction in COPD [38] Emerging research is 
suggesting that pulmonary rehabilitation may be an aid in smoking cessation [88]. As 
well, further research is needed to determine the optimization of pulmonary rehabilitation 
programs (dose, duration and frequency) [50, 80]. 
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1.6. Clinical Assessment  
1.6.1. Diagnosis 
Pulmonary function tests, such as spirometry and measurement of lung volumes and 
diffusion capacities are key to confirm diagnosis and determine disease severity [18]. A 
spirometry test should be undertaken by current or former smokers over the age of 40 
years if they are demonstrating any of the following symptoms; regular cough either with 
or without phlegm, feelings of shortness of breath while performing simple chores, 
wheezing at night or under exertion, or susceptibility to frequent colds lasting longer than 
usual [2]. For diagnosis of COPD, a post-bronchodilation spirometry needs to be 
performed, where FEV1 and FVC are measured. A ratio of FEV1 over FVC less than or 
equal to 0.7 is indicative of airflow limitation [1, 8].  Further pulmonary function tests 
can be conducted to track the progression of the disease, to help clarify diagnostic 
uncertainties and determine patient eligibility for surgical intervention [1]. Additional 
tests such as a chest x-ray may be helpful in identifying other comorbidities and in 
discarding alternative diagnoses [1]. 
1.6.2. Other investigations  
A complete medical assessment should be conducted evaluating risk factors, family 
history of COPD, past medical history (ie. frequent childhood respiratory infections, 
allergies, asthma or other respiratory conditions), and the presence of concurrent 
comorbidities, in addition to the evaluation of the patient’s current management, family 
support, history of exacerbations and hospitalizations, modifications of risk factors (ie. 
through smoking cessation) and pharmacotherapy treatment and response [18]. A 
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physical assessment should be conducted, yet physical signs of airflow limitation may not 
become apparent until significant impairment has occurred and are therefore not used for 
diagnosis [89, 90]. Physical examination may be useful in detecting changes in the chest 
wall; in cases of hyperinflation, a more rapid shallow RR may be noticeable, while lower 
leg and ankle edema may be detectable in the presence of right heart failure [1]. 
Arterial blood gas measurements should be done under stable conditions and are 
especially important in the more advanced stages of the disease, when FEV1 is less than 
50% of the predicted value or when clinical signs of respiratory failure (PaO2  
<60mmHg) or right heart failure are present (ie. cyanosis, ankle swelling) [1]. 
Finally, evaluations of exercise intolerance are also important to help indicate a patient’s 
current health status as well as predict their future prognosis [1]. Exercise tests have 
become routinely used for the clinical evaluation of COPD patients [91]. 
1.6.3. Exercise testing  
Cardiopulmonary exercise testing (CPET) provides a comprehensive measure of the 
global response of the major systems including the cardiac, pulmonary and muscular 
systems [42]. CPET objectively measures functional capacities and impairment, limiting 
factors to exercise, pathophysiological respiratory mechanisms and exertional symptoms 
[42, 92-95].  Overall health status has been shown to be more strongly correlated with 
exercise tolerance than with measures of resting pulmonary and cardiac function [42]. 
Greater awareness of the benefits of reliably predicting exercise performance and 
functional capacity has lead to the increased use exercise tolerance testing [42, 53]. In 
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addition, technological advancements have made the CPET equipment much more user-
friendly [53].   
The most common indications to perform exercise testing are to diagnose the presence of 
cardiovascular and/or respiratory diseases, to evaluate disease severity, prognosis and 
response to treatment in individuals with known disease, and to determine 
exercise/functional capacity for preoperative purposes, disability assessment, return to 
work evaluation and/or exercise prescription [42].  Exercise testing is thus useful in all 
phases of clinical decision making, from diagnosis to assessment of severity, disease 
progression, prognosis, and response to treatment [42].   
Exercise testing may be conducted either in the field or in a laboratory-based setting [53]. 
Field tests may be more reflective of daily activities (e.g. six-minute walk, shuttle walk, 
stair-climbing test, etc.) [92]. In a laboratory setting, the treadmill and stationary cycle 
ergometer are the preferred modes of testing [42]. Each mode of exercise has its own 
advantages and disadvantages. Research has revealed that it is most efficient to utilize 
larger muscle groups during testing, whereby greater physical stress is then exerted [42]. 
With treadmill testing, a larger muscle mass is utilized as compared to cycle ergometry; 
this is reflected through the physiological measure of maximal oxygen consumption 
(VO2), which typically reaches higher values when testing is performed on a treadmill 
than on a cycle ergometer [42]. However, the cycle ergometer is less expensive and 
requires less space than a treadmill [42]. Moreover, the cycle ergometer is less prone to 
introduce movement and noise artifact into measurements (e.g. electrocardiogram (ECG) 
and blood pressure (BP) monitoring).  In general, if exercise testing is being used to 
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provide a prescription for subsequent exercise training, then it may be advantageous to 
use the same exercise modality in testing as in training [42].  
Several protocols exist to evaluate exercise response in patients with COPD. The 
protocols can be classified by whether they are (i) maximal or sub-maximal in nature, (ii) 
incremental or constant load, and (iii) externally paced or self-paced [53]. A test is 
termed maximal if volitional fatigue is attained, whereas it is termed sub-maximal if it is 
stopped when a pre-determined endpoint has been reached (e.g. 80% of maximum 
predicted heart rate (HR)) [53]. Incremental exercise tests submit patients to a 
consistently increasing workload, whereas constant-load exercise tests subject patients to 
a fixed work rate, often determined as a percentage of their peak capacity [53]. An 
externally-paced protocol is one where the workload (e.g. cycling resistance, walking 
speed) is imposed on the patient, whereas self-paced protocols allow the patients to 
dictate their own work rate (e.g. six-minute walk test) [53].  
Within a COPD patient population, there currently exists no consensus as to which 
protocol is best suited to evaluate exercise tolerance [53]. The different modalities for 
exercise testing do not demonstrate the same responsiveness to each test when dealing 
with patients with COPD [58, 61, 96-99]. Exercise intolerance in COPD manifests itself 
in a complex array of interactions in symptomology, ventilatory and respiratory 
mechanics impairment, gas-exchange limitations and peripheral muscle fatigue [58]. 
Furthermore, in patients with COPD, exercise termination may occur prior to the 
occurrence of predictors of maximal exercise attainment, such as the attainment of 
maximal VO2 [58]. Therefore, it is important to comprehensively evaluate these 
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measures. According to the American Thoracic Society and the American College of 
Chest Physicians, the most commonly used test with COPD patients in clinical practice is 
the maximal incremental cycle ergometer test [42].  
Once the appropriate protocol has been selected for clinical exercise testing, it is essential 
to take into consideration the nature of the measured variables as well as their validity 
and reproducibility [42]. The main measurements involved in CPET typically include 
respiratory gas exchange (VO2, carbon dioxide output (VCO2), and VE, ECG, HR, BP, 
and SpO2 [100]. Values of HR, VO2, SpO2, VE, ventilatory threshold (VT), and RR 
reached during maximal progressive exercise are all highly reproducible [101, 102]. The 
response obtained from the first exercise procedure is considered representative [102, 
103]. Factors that may contribute to variability in these measurements include changes in 
clinical status, symptoms, and medication(s), patient motivation, patient instructions, test 
procedures, equipment calibration errors, and the time of day [42]. These factors must be 
meticulously controlled to minimize discrepancies in measured exercise responses [42]. 
Changes in clinical status may occur as COPD is a progressive disease. As a susceptible 
patient population, symptoms may be subject to the effects of respiratory exacerbations. 
Additions or changes to medications are also common in this patient population. Patient 
instructions and test procedures are linked and should both optimally be standardized 
[104]. Offering encouragement to the patient has been demonstrated to have a significant 
effect on exercise performance, probably via patient motivation; encouragements should 
therefore be avoided or, perhaps preferably, standardized [104]. Equipment calibration is 
recommended prior to each test [42] since changes in environmental conditions can play 
a crucial role and invite variability into the experiment’s results. Finally, the American 
36 
 
Thoracic Society guidelines have recommended testing to be undertaken at the same time 
of day [42] since significant diurnal variation in physiological measures have previously 
been reported [102, 103].  This potential confounding factor is discussed in details in the 
next section.  
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1.7. The Basis of Diurnal Variations in Various Physiological Parameters 
Chronobiology is the study of time-dependent changes in physiological variables [105]. 
Circadian rhythms are characterized as recurring 24-hour patterns of physiological 
functions and are the result of the endogenous oscillator [105-108]. Endogenous rhythms 
are self-sustaining rhythms and are thought to originate from the suprachiasmatic nuclei 
(SCN) in the anterior hypothalamus [105, 108-110]. The endogenous rhythms are the 
body’s internal biological clock or pacemaker [105, 108-110]. Therefore, the circadian 
rhythm is thought to be the causal factor in biological rhythms [108]. However, further 
research is required in this area as the SCN has not conclusively been identified as the 
sole regulator of rhythmicity [105].  
Biological rhythms can further be described as diurnal, where an observed 24 hour 
pattern can be identified [108]. A diurnal rhythm may originate either from internal cues, 
which are known as endogenous rhythms, or through external influences, which are 
known as exogenous rhythms [108]. Exogenous influences can be affected by outside 
influences such as behavioral or environmental conditions [109]. Factors which influence 
exogenous rhythms include activity, meals, posture as well as light, temperature and 
allergens [105, 108, 109].  
Laboratory constant routine protocols may be used to control for the effect of masking 
[108]. The objective behind a constant routine protocol is to eliminate as many external 
cues as possible and to unmask the underlying endogenous circadian rhythm [108]. 
Performing studies with constant routines are inherently more challenging and are 
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therefore less reported, diurnal studies are incidentally more commonly used in clinical 
studies as they are more closely related to real life situations [108]. 
Circadian variations in many physiological variables have been clearly established in the 
literature [111, 112]. Variations have been demonstrated in pulmonary function, 
metabolic (VO2 and VCO2, VE) and cardiorespiratory responses (HR, and BP), [105, 
112]. When considering rhythms of physiological function related to exercise response, 
resting cyclical rhythms must be first considered [106]. Physiological rhythms detected at 
rest may be cancelled or weakened, maintained or intensified under active conditions 
[106]. Below is a description of the circadian variations documented to date for the main 
pulmonary, metabolic and cardiorespiratory variables related to resting and exercise 
performance. 
1.7.1 Pulmonary function 
Chronobiology is particularly significant when applying it to pulmonary function [107, 
113]. Indices of lung function have been shown to differ throughout the day as a 
consequence of changes in airway resistance [106]. Changes in airway resistance may be 
signaled in patients by an increase in their symptoms, namely an increase in shortness of 
breath. Patients with airway obstruction often report a worsening of their symptoms at 
specific times of the day [113, 114]. However, it remains unclear when COPD patients 
are affected the most. Based on patient reports, varying patterns have been noted: a 
morning reduction, an evening reduction, a double dip pattern where both a morning and 
evening reduction is observed, or no change in pattern [115-117]. Knowledge of the 
patient’s regular patterns of reduced airflow is more likely to be useful in planning 
preventative therapeutic strategies and optimizing treatments [107, 115]. Even small 
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increases in airway obstruction may be enough to burden those with pulmonary disease 
and result in severe disability [107, 114]. 
Pulmonary function may also be objectively represented by the amount of airway 
resistance, measured by forced expiratory flow (FEV1) and peak expiratory flow (PEF), 
which vary with time of day and are at their lowest between 0300 hours and 0800 hours 
[117-119]. Arguably, airway caliber is the foremost determinant of diurnal variation in 
ventilation [117]. This has been extensively researched in an asthmatic population where 
there is a clear increase in airway resistance in the morning [120]. In healthy individuals, 
there is a peak in airway resistance in the morning followed by the lowest airway 
resistance at noon and by an increase in resistance in the afternoon [107].  
In COPD, other variables may play a detrimental role, where hyperinflation of the lungs 
appears to be greater in the morning [40] while bronchiole secretions and mucous 
production are greater in the morning and evening [121].   Carbon monoxide diffusion 
capacity (DLCO) measures were found to peak in the morning between 0800 and 0900 
hours and progressively decrease into the evening [107, 122]. The decrease in DLCO has 
been postulated to cause or be linked to the corresponding fall in hemoglobin and 
hematocrit [122]. Similarly higher alveolar volumes (VA) have been identified in the 
morning and decreases into the evening [123]. Potentially VA may contribute to the 
decrease observed in DLCO [123]. The mechanism of change for VA is not completely 
understood, however it has been proposed that the lung surface area may decrease and a 
smaller area for gas exchange would be the reasoning behind the changes observed in 
DLCO [123]. Additionally, the change in DLCO may be related to changes in lung recoil 
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pressure [124]. A greater decline in DLCO values may depend on the posture maintained 
throughout the day (e.g. standing erect, bank teller or if an individual is seated, secretary) 
[123]. An erect posture imposes a downwards gradient, shifting blood and tissue fluid, to 
the lower body intensifying the decrease in DLCO [122].  
1.7.2 Metabolic response 
Evident during resting conditions are rhythms in VO2, VE, and VCO2 [125, 126]. A 
positive correlation exists between VO2 and VCO2 [125]. At rest, VO2 and VE coincide in 
phase, where their values are greatest at 1800 hours and are at their lowest at 
approximately 0400 to 0600 hours [125, 127]. Meanwhile, in healthy subjects no change 
in respiratory exchange ratio (RER), the ratio of VCO2/VO2, has been seen at rest, 
suggesting that substrate utilization does not vary throughout the day [112, 126].   
Under increasing exercise intensities, these rhythms seem to persist with light, moderate 
and peak exercise intensities [105, 106, 126]. Most notably, the rhythm observed in VE is 
amplified at light to moderate intensities as airway resistance increases the resistance to 
breathing [106]. However, at maximum capacity, rhythms for VO2, VCO2 and VE have 
been shown to be less identifiable [126]. Interestingly, the VT, which determines the point 
where VCO2 or VE begins to increase disproportionately from VO2, has not been shown 
to vary irrespective of time of day [125, 126, 128].  
A distinction between peak and maximal capacities needs to be made. During exercise, 
maximum is defined as the point where volitional fatigue is achieved [53]. In a COPD 
patient population, there is no universally accepted marker for the attainment of maximal 
capacity, as leg dyspnea and shortness of breath are important limiting factors [42]. The 
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gold standard for determining VO2max has typically been if a plateau in VO2 had been 
achieved [42]. In a COPD patient population, a clear plateau may not be achieved before 
symptoms limit exercise capacity [42]. Therefore, a maximal test may be difficult to 
attain. Yet literature seems to suggest that VO2max remains stable and is independent of 
time of day [106, 125]. Debate exists as to whether VO2max varies with time of day and 
whether a true VO2max is attained through exercise testing; if not, it can lead to 
erroneous conclusions [129-131].  
1.7.3 Cardiorespiratory response 
Within the cardiorespiratory response, the research on HR rhythms variability is unclear 
[105]. Some studies have suggested that heart rate did not vary depending on time of day 
[132, 133]. In contrast, several others have shown that HR demonstrates a time of day 
rhythm, which is evident under constant routine, at rest, and during exercise (at light to 
moderate and maximal exercise intensities) [106, 108]. These later investigations have 
documented a peak in HR between 1400 and 1500 hours [105, 126]. Within a cardiac 
population, a significant increase in HR has been perceived in the afternoon, when 
individuals are on medications such as beta-blockers [134].  
With BP, external influences can muddy the possible circadian rhythms [105]. BP may be 
influenced by behavioral and environmental factors, however under a constant routine 
protocol in healthy individuals, no significant circadian variations were detected [108]. In 
individuals with coronary artery disease, BP was shown to peak both in the early morning 
and in the evening [135]. Therefore, further research is required in chronic disease states.  
1.7.4 Confounding factors 
1.7.4.1 Sleep and alertness 
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Circadian rhythm controls sleep timing and wakefulness, consequently sleep disorders 
have been linked to perturbations in the circadian rhythm [136].  The sleep-wake cycle 
affects circadian rhythmicity in that sleep lost affects cognitive function more so than 
gross motor actions [106]. Gross motor tasks and lung function have been shown to be 
more resistant to the effects of sleep deprivations in healthy individuals [106]. A single 
night of recovery is typically enough to reverse the effects of sleep deprivation [106, 
109]. However, patients with pulmonary disease are more vulnerable to sleep loss for a 
number of reasons, including symptom presentation throughout the night, insomnia and 
esophageal reflux; side effects of certain respiratory medications [137, 138]. A measure 
of the quantity and quality of sleep should preferentially be conducted, as decreased 
alertness may affect performance under clinical exercise testing conditions [139]. 
However, short bouts of exercise (e.g. a warm up) may help increase arousal level, 
counteracting detrimental effects, for an unspecified period of time [105, 106]. 
1.7.4.2 Clock time and circadian time  
Humans are entrained by a 24 hour clock, where they habitually sleep during the night 
and are active during the day [106]. A normal physiological range is between 24 and 24.3 
hours [140]. It should be noted that clock time is not always the same as circadian 
(biological) time [105, 141]. Biological rhythms are adaptive to change [142]. Changes to 
routine, such as when conducting shift work (e.g. night shift) or when there is a shift in 
phase (e.g. after travelling through different time zones), can affect performance [106]. 
Additionally, chronotype – i.e. whether an individual is characterized as a morning or 
evening type – can shift circadian phases. Morning types have been shown to 
demonstrate an advanced phase of about two hours on average, going to sleep earlier and 
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waking up earlier [128]. This can have implications on performance, where morning 
types may be more alert than their evening-type counterparts for morning evaluations and 
vice versa for late afternoon evaluations. Diurnal variations in VO2max in healthy 
individuals were found to be greater in the afternoon in evening types as compared to 
morning types, despite similar exercise duration seen in both groups [128].  
1.7.4.3 Environmental conditions 
Environmental conditions may affect diurnal rhythm in that morning types are exposed to 
greater amounts of light than an evening type of individual [106, 143]. Greater light 
exposure may consequently entrain an earlier phase type [106]. Older individuals have 
been observed to demonstrate an earlier phase shift and a positive correlation has been 
found between age and morningness [144]. Older individuals have been shown to yield 
weaker cues in COPD; where the disease follows a progressive path and the patient 
population is often comprised of older individuals [145]. However, in a more physically 
active population, greater rhythm amplitudes were demonstrated [146]. The amplitude of 











COPD is associated with frequent changes in clinical status, as a result of the progressive 
nature of the disease.  In addition, circadian/diurnal variations in many physiological 
variables have been established in this patient population. Indeed, indices of lung 
function as well as symptom perception have been shown to vary throughout the day, 
generally as a consequence of changes in airway resistance. The functional implications 
of such circadian variations have seldom been investigated. Given that even small 
increases in airway obstruction can significantly burden those with pulmonary disease, 
circadian variations in physiological parameters are likely to have important clinical 
repercussions in COPD patients.  
CPET is a commonly used tool which allows the evaluation of the global and integrative 
response of the major systems. It provides exclusive information above what is found 
from resting measures. Current exercise testing guidelines recommend that repeated 
exercise testing be undertaken at the same time of day to avoid the potential confounding 
effect of circadian variations in exercise measures. Yet, in COPD patients, the impact of 
time of day on exercise performance remains to be examined. The general aim of the 
present study was to investigate the impact of time of day on the acute response to 
exercise in individuals with COPD, to assess the implications of daily biological 











Research Objectives and Hypothesis 
Primary Research Objective:  
1) To evaluate, in individuals with COPD, the effect of time of day on peak exercise 
capacity. 
Secondary Research Objectives: 
1) To evaluate the effect of time of day on resting pulmonary function (FEV1, FVC). 
2) To evaluate the effect of time of day on resting and exercising physiological response 
(VO2, VCO2, VE, HR, etc.). 
3) To evaluate the effect of time of day on resting and exercising symptoms (dyspnea and 
leg fatigue). 
Research Hypotheses 
It was hypothesized that significant diurnal variations would be observed in a COPD 
population both at rest and during exercise. More specifically, our hypotheses were: 
1) Peak exercise capacity will be lowest in the morning and highest in the afternoon. 
2) Pulmonary function will be lowest in the morning and highest at noon. 
3) Metabolic responses (VO2, VCO2, VE) will be highest in the afternoon. HR will be 
greatest in the afternoon, while BP will be greatest in the morning.  
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Purpose: Indices of lung function and symptoms have been shown to vary throughout 
the day. In COPD, these variations may have clinical repercussions. The general aim of 
this study was to investigate the impact of time of day on the acute response to exercise 
in individuals with COPD. Methods: Subjects followed a counterbalanced randomized 
design, performing three symptom-limited incremental cycling tests -each preceded by a 
pulmonary function test- at 08:00, 12:00, and 16:00. COPD medications were withdrawn 
6-24 hours prior to each test. Physiological response was measured breath by breath at 
rest and during exercise. Changes in outcomes were assessed with repeated-measures 
ANOVAs using the General Linear Model. Friedman tests were performed for non-
parametric data. Results: Fourteen subjects (9 men, 5 women) aged 71 ± 7 years with 
moderate airflow obstruction (FEV1: 58 ± 13% predicted) completed all evaluations. No 
overall time effect was found for peak exercise capacity (p= 0.22) or pulmonary function. 
However, changes at or beyond the suggested minimal clinically important difference 
were observed in nine of the 14 subjects for both variables. Resting RER was higher in 
the morning than at other time points (p = 0.001). Trends for time effects were found for 
mean VT (p = 0.096) and HR (p = 0.08). VT tended to decrease throughout the day, 
while HR tended to increase from morning to afternoon. Conclusion: These results 
suggest that diurnal variations in the acute response to exercise may be heterogeneous 





Chronic Obstructive Pulmonary Disease (COPD) is a progressive and partially 
irreversible disease characterized by chronic airflow limitation [1]. It is the fourth leading 
cause of death in the world and in Canada [1]. As a result of the progressive nature of the 
disease, COPD is associated with frequent changes in clinical status over a period of 
time. Yet indices of lung function and symptom perception have also been shown to vary 
over the period of a single day.  
Chronobiology is the study of time-dependent changes in physiological variables [105]. 
Variations occurring over a 24-hour period can be classified as either circadian or diurnal 
[105, 106, 107 ]. Circadian rhythms are the result of the endogenous oscillator, which is 
described as being the causal factor in biological rhythms [108]. The endogenous 
rhythms are the body’s internal biological clock, which is a self-sustaining rhythm 
thought to originate from the suprachiasmatic nuclei (SCN) in the anterior hypothalamus 
[105, 108-110]. Biological rhythms can be additionally influenced by external cues, 
creating 24-hour patterns which are known as diurnal variations [108]. The external cues 
are exogenous influences such as behavioral or environmental conditions [108, 109]. 
Factors which influence exogenous rhythms include activity, meals, posture as well as 
light, temperature and allergens [105, 108, 109]. 
In a more susceptible population such as COPD patients, given that even small increases 
in airway obstruction can pose a significant burden, the variations in physiological 
parameters are likely to have important clinical repercussions [107, 114]. Spirometry can 
be used to objectively measure changes in pulmonary function,  yet overall health status 
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has been shown to be more strongly correlated with exercise tolerance [42]. A greater 
awareness of the benefits of reliably predicting exercise performance and functional 
capacity, has lead to the routine use of CPET [42]. CPET measures the global and 
integrative response of the major systems and provides exclusive information above what 
is found from resting measures [53]. In healthy populations, physiological rhythms 
detected at rest have been shown to be either obliterated, attenuated, maintained or 
amplified under exercise conditions [106]. In COPD patients, the potential impact of time 
of day on exercise tolerance has yet to be examined.  
The general aim of the proposed study was to determine the impact of time of day on the 
acute response to exercise in individuals with COPD. More specifically, the primary 
objective was to evaluate, in individuals with COPD, the effect of time of day on peak 
exercise capacity. Secondary objectives were to evaluate the effect of time of day on i) 
resting pulmonary function, ii) resting and exercising physiological response (VO2, 
VCO2, VE, HR, BP), and iii) resting and exercising symptoms (dyspnea and leg fatigue). 
Methods 
Study Design and Procedure 
The study followed a counterbalanced research design, where each participant acted as 
his/her own control. Candidates who met the eligibility criteria agreed to take part in the 
study, and obtained medical clearance for the exercise testing protocol were asked to 
come to the research facility for a total of four visits (Figure 4).  
50 
 
The first visit consisted of baseline measurements, explanation of the patient folder, and 
familiarization to the testing procedure. Baseline measurements included demographics 
and clinical information (age, sex, height, weight and body mass index (weight/height
2
)), 
chronotype assessment and pulmonary function testing. Participants were then instructed 
on how to complete the patient folder, which included questions about sleep quality and 
quantity, dietary and pharmacological intake, and physical activity, to be filled several 
times daily throughout the study period (Appendix A). Familiarization to the testing 
procedure consisted of allowing subjects to practice the symptom limited cycle ergometer 
test. More specifically, after receiving the same instructions as prior to a real test and 
after having been introduced to the testing equipment (facemask, electrodes, BP monitor, 
oxymeter, Borg scale, etc.), participants embarked on the cycle ergometer and pedaled at 
the prescribed rate until they felt comfortable with the procedure.  
Subjects then entered the counterbalanced design (visits 2-4) where they each completed 
three symptom-limited incremental cycling exercise tests, each conducted on a different 
day, at a different time of day (08:00, 12:00, and 16:00, ± 15 minutes), and each preceded 
by a pulmonary function test. The selected testing times were chosen to cover the range 
of hours when exercise tests are typically conducted in clinical practice. In order to limit 
the potential confounding effect of learning on test performance, the sequence of testing 
times was determined through block randomization; however, participant availability and 
accessibility to medical supervision were also considered. Study visits were separated by 
at least 36 hours, but no more than 1 week.  
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In order to limit the potential confounding effect of COPD medication on diurnal 
variations in exercise performance, subjects were asked to withhold the following 
medications before visits 2-4: short acting 2-agonists (6 hours), short-acting 
anticholinergic agents (6 hours), combination products of short-acting agents (6 hours), 
long acting 2-agonists (24 hours), inhaled corticosteroids (24 hours), and combination 
products of long-acting 2-agonists and inhaled corticosteroids (24 hours). Subjects 
taking a long-acting anticholinergic agent (tiotropium) were switched to a short-acting 
anticholinergic agent (ipratropium bromide) 40 g QID by a collaborating respirologist 2 
weeks prior to the beginning of the trial and for the duration of the trial (approximately 1 
week). These subjects were asked to withhold their short-acting agent 6 hours prior to 
visits 2-4, as others. They were returned to their original medication regimen upon 
completion of their last study visit.  
The research protocol was approved by the institutional ethics committee and a signed 
informed consent was obtained from each subject. 
Subjects 
Subjects were recruited from the outpatient COPD clinic at Hôpital du Sacré-Coeur de 
Montréal as well as from a pool of patients who had completed previous studies in our 
laboratory and who had consented to be contacted for future investigations. Eligibility 
was ascertained according to the following inclusion criteria: 1) clinically stable COPD; 
2) age 40 years or older; 3) smoking history of at least 10 American pack-years (20 
cigarettes per pack); 4) post-bronchodilation FEV1 less than 80% of the predicted normal 
value; 5) FEV1 to FVC ratio less than 0.7; and 6) previous experience of exercise testing. 
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Participants were deemed ineligible for the study if the following exclusion criteria were 
present: 1) exacerbation of respiratory symptoms in the past 4 weeks (change in dyspnea 
or volume/colour of sputum, need for antibiotic treatment, or need for hospitalization); 2) 
any contraindication to exercise testing based on guidelines from the American Thoracic 
Society [42]; 3) any active condition other than COPD that can influence exercise 
tolerance (unstable coronary heart disease, left congestive heart failure, neoplasia, severe 
claudication, severe arthritis, etc.); 4) need for O2 therapy; and 5) prescribed 
Theophylline. These eligibility criteria were mostly meant to differentiate COPD from 
other respiratory diseases and to ensure clinical stability and patient safety.   
Assessments 
Chronotype Questionnaire 
At the initial visit, subjects completed the morning-evening questionnaire (MEQ) [148]. 
MEQ is a 19-item scale which has been established as a valid measure and classifies 
subjects as either morning, intermediate or evening types [148, 149]. Scores on the MEQ 
vary from 16 to 86; high scores (59-86) identify morning-type individuals, low scores 
(16-41) correspond to evening-types and scores from 42-58 are intermediate or neither 
types. Morning types, as compared to evening types, loosely follow an advanced timing 
of the endogenous circadian clock. 
Sleep Measures 
The Pittsburgh Sleep Diary is used to evaluate the subjects’ sleep quantity and quality 
[150]. Two questionnaires were given: a morning questionnaire that assess the subjects’ 
sleep the night prior to the day of the evaluation as well as their morning routine, and an 
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evening questionnaire based on the current events during the day leading up to sleep. 
This instrument has demonstrated to be both a valid and sensitive measure [150]. 
In addition, during the period of testing, patients were asked to respect the targeted 8 
hours of sleep per night; an interval of 30 minutes was accepted for both bedtime and 
wake time; therefore predicted sleep duration could vary between 7 and 9 hours.  
Dietary Intake 
Subjects completed a food journal during the week of their evaluations.  An explanation 
on how to complete the dietary journal was given at the initial visit. The subjects were 
asked to log the date and time that meals were ingested. 
Physical Activity Levels 
Subjects completed a physical activity journal during the week of their evaluations.  An 
explanation on how to complete the journal was given at the initial visit. The subjects 
were asked if they performed any physical activity during the course of the day and, if so, 
to indicate the time and type of activity which was performed. 
Pulmonary Function Testing 
Spirometry was performed at baseline and before each evaluation according to 
recommended techniques [41]. Values were compared to predicted normal values from 
the European Community for Coal and Steel/European Respiratory Society [151].  
Exercise Testing 
Exercise testing consisted of symptom-limited incremental cycling exercise tests. This 
protocol was selected as it is frequently used in respirology [152]. Subjects were seated 
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on an electromagnetically braked cycle ergometer (Ergoselect 200P, Ergoline, Germany) 
and connected to a cardio-respiratory circuit through a mouthpiece. The cardio-
respiratory circuit consisted of a digital volume sensor (TripleV), O2 and CO2 analyzers, 
and 12 –lead ECG (Jaeger Oxycon Pro, CareFusion, Germany). After five minutes of rest 
and three minutes of unloaded pedalling, the workload was increased in a stepwise 
manner every minute, up to the individual’s maximal capacity. The workload was 
increased by 5-10 watt increments (5-watt increments for subjects with a predicted work 
rate < 50 watts; 10-watt increments for those with a predicted peak work rate > 50 watts).  
Gas exchange parameters (VE, O2 uptake, CO2 excretion), pulse oximetry (SpO2), and 
HR were measured at rest and during exercise on a breath-by-breath basis. Inspiratory 
capacities were conducted at rest and every other minute during the exercise test, in 
accordance to the American Thoracic Society/European Respiratory Society guidelines, 
to evaluate the degree of lung hyperinflation [41, 43]. Standardized instructions were 
given prior to each test and any encouragement given during the test was standardised, 
every 30 seconds. Peak exercise capacity was defined as the highest work rate maintained 
at a pedalling speed of at least 50 revolutions per minute for a minimum of 30 seconds. 
These tests were completed under medical supervision. 
Symptoms  
The common factors that limit exercise in COPD patients are dyspnea and leg fatigue 
[60]. These factors were measured at rest and every other minute during the exercise tests 





To determine the overall effect of time of day (independent variable with three levels: 
8:00, 12:00, and 16:00) on peak exercise capacity and resting pulmonary function 
(dependent variables), one way repeated-measures analyses of variance (ANOVAs) were 
conducted using the General Linear Model. If a significant main effect was obtained, 
pairwise comparisons with Bonferroni corrections were conducted to identify between 
which time points the differences occurred. Friedman non-parametric tests were 
performed to analyze the overall effect of time of day on any non-parametric data.   
To further investigate the primary outcome of peak exercise capacity and potentially 
generate new hypotheses, a series of interaction analyses were conducted using the 
General Linear Model. These exploratory analyses examined the interactive effect of time 
of day (independent variable 1) with a number of descriptive measures and potential 
confounders (independent variable 2) on peak exercise capacity (dependent variable). 
The descriptive measures examined, which were believed to be potential covariates in the 
relationship between time of day and exercise performance, were chronotype (morning 
vs. intermediate), age (under 70 vs. 70 and over), sex (male vs. female), and BMI (normal 
weight vs. overweight to obese). The potential confounders examined where last dietary 
intake (below the median split; at or above the median split), and sleep quantity (less than 
8 hours vs. 8 hours or more).  Post hoc Student Newman-Keuls (SNK) were performed 
for any significant findings. 
Finally, changes in physiological measures and symptoms were examined between the 
two states (resting and peak) and at the three levels of testing times (08:00, 12:00 and 
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16:00) with a 2x3 repeated-measures ANOVA. If a significant interaction between state 
and testing time was detected, simple main effect tests were conducted to identify the 
state (resting or peak) for which differences between testing times were significant. If a 
significant simple main effect was obtained, pairwise comparisons with Bonferroni 
corrections were conducted to identify between which testing times the differences 
occurred. For these analyses, any non-parametric data was transformed using the square 
root function to parametric data and was analyzed. Analyses were conducted at the 5% 
level of significance and performed with SPSS version 18.0 (Chicago, IL).  
Results 
Subjects 
A total of 81 patients were contacted, 76 of which were eligible to take part in the study, 
and 5 of which were ineligible due to reasons such as being prescribed theophylline (n 
=2), being prescribed O2 (n = 1), working the night shift (n =1) and not meeting the 
pulmonary function criteria (n = 1). Of the 76 eligible patients, 41 patients refused, the 
most predominant reasons being lack of interest (n = 8), health reasons (n = 8), 
transportation limitations (n = 6), schedule conflict (n = 6), not wanting to change their 
medications (n= 3) or various other reasons (n = 10). In total, 14 patients accepted to 
participate and completed all measurements. The baseline characteristics of the study 
group are presented in Table 2. The sample was composed of a majority of older, slightly 
overweight, morning-type, males, with moderate to severe airflow obstruction based on 




Effect of Time of Day on Peak Exercise Capacity 
Individual results and group means for peak exercise capacity are shown in Figure 5. No 
significant overall time effect for peak exercise capacity was found (p = 0.22, eta
2
 = 
0.11). Exploratory analyses looking at potential interactive effects of time of day and a 
number of descriptive measures on peak exercise capacity detected no significant 
interactions between testing time and chronotype (p = 0.851), age (p = 0.923), sex (p = 
0.784), and BMI (p = 0.61) (Figure 6).  
Time spent in bed was found to be significantly less the night prior to the morning visit 
(8:00) as compared to the other two visits (p = 0.01, eta
2
 = 0.41), but the interaction 
between time of day and sleep quantity on peak exercise capacity was not statistically 
significant (p = 0.368). Likewise, the time since last dietary intake was found to be 
shorter for the morning visit than for the noon and afternoon visits (p = 0.036). However, 
no significant interaction effect was found between testing time and time since last 
dietary intake on peak exercise capacity (p = 0.937). 
Effect of Time of Day on Pulmonary Function 
The individual data and group means for FEV1, FVC, and FEV1/FVC values obtained at 
rest prior to each exercise tests are shown in Figure 7. No significant overall time effect 
was detected for FEV1 (p = 0.56, eta
2
 = 0.04), FVC (p = 0.79, eta
2
 = 0.18), or FEV1 /FVC 
(p = 0.87, eta
2
 = 0.01). Likewise, no significant overall effect of time was found for IC 
measures obtained at rest (p = 0.32, eta
2
 = 0.08) and during exercise (p = 0.91, eta
2
 = 




Effect of Time of Day on Resting and Exercising Physiological Response 
Group means for resting and peak VO2, VCO2, VE, RR, VT, SpO2, HR, and BP, are 
shown in Table 3. A significant effect of testing state (rest vs. peak) was detected for all 
variables but diastolic BP. More specifically, significant increases from rest to peak were 
seen in VO2, VCO2, RER, VE, VT, RR, HR, and systolic BP (p < 0.001 for all). In return, 
a significant decrease from rest to peak was found for SpO2 (p < 0.001). 
A significant interaction between testing state and time of day was detected for RER (p = 
0.002). Simple main effect tests further revealed that the effect of time of day on RER 
was significant at rest only (p = 0.001). Results from pairwise comparisons suggested that 
resting RER was significantly higher in the morning than at the other two time points (p 
< 0.05 after Bonferroni correction). 
Furthermore, a trend was seen for the overall effect of testing time on VT (p = 0.096). 
More specifically, VT tended to decrease throughout the day. Post-hoc comparisons did 
not reveal any significant differences between pairs of testing times, but a trend was 
found between the earliest and latest tests. Finally, a trend was found for the effect of 
testing time on HR (p = 0.082). Pairwise comparisons did not reveal any significant 
difference between the three times of day, but HR tended to increase throughout the day. 
No other significant effect was found. 
Effect of Time of Day on Resting and Exercising Symptom Perception 
A significant effect of testing state was detected for symptoms, as subjects’ ratings of 
dyspnea and leg fatigue significantly increased from rest to peak (p < 0.001 for both). No 
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time effect or state by time interaction were found for either dyspnea or leg fatigue. The 
group means are shown in Table 4.  
Discussion 
Effect of Time of Day on Peak Exercise Capacity 
The primary objective of the present study was to evaluate the effect of time of day on 
peak exercise capacity in individuals with COPD. It was hypothesized that significant 
diurnal variations in exercise capacity would occur and, more precisely, that a greater 
peak workrate would be achieved in the afternoon than in the morning. However, our 
findings do not support this hypothesis, as no time effect was found for peak exercise 
capacity in a group of individuals with moderate to severe airflow obstruction. 
Previous research has suggested that aerobic capacity follows the circadian rhythm of 
body temperature, peaking in the afternoon [105, 110, 132, 133].  However, physiological 
rhythms detected during exercise have also been shown to vary depending on the 
intensity of the exercise, being either amplified or maintained, abolished or weakened 
under different intensities [106, 132, 133]. Various exercise testing protocols may 
therefore have different capabilities to detect circadian rhythms in exercise tolerance 
depending on their intensity level. In the present study, the symptom-limited incremental 
cycle ergometer protocol was chosen because it is the most commonly used protocol in 
clinical practice in respirology [42]. Yet, there is no current consensus as to which 
protocol is optimal to assess exercise tolerance in COPD patients. Maximal or peak tests 
have been shown to lack sensitivity to changes in exercise tolerance after various 
interventions, such as pulmonary rehabilitation or bronchodilation [98, 154, 155]. These 
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protocols may thus also lack sensitivity to circadian variations in exercise tolerance. 
Constant-load protocols, which submit patients to a fixed workrate, have gained 
popularity in latest years because of their high responsiveness to treatment and because 
they are believed to more closely represent the intensity of daily activities [42, 43, 97, 
155, 156]. These protocols could therefore also be more prone to detect circadian 
variations in exercise tolerance than maximal tests. However, constant-load or endurance 
exercise tests are typically conducted at a certain percentage of the highest workrate 
achieved on a maximal incremental test [42]. As such, circadian variations in the 
response to peak exercise had to be investigated first before studies examining variations 
in the response to constant-load testing could be conducted. 
In this study, changes in peak exercise capacity across the different testing times were 
heterogeneous within the study sample. Indeed, although no overall time effect was 
detected for exercise capacity, a number of patterns occurred, as shown by the individual 
data across the three testing times (Figure 5). It was hypothesized that the different 
patterns observed were perhaps influenced by other factors [106]. Therefore, analyses 
were performed to examine whether chronotype, age, sex, BMI, sleep quantity the night 
before or time since last dietary intake interacted with time of day to affect exercise 
capacity. Sleep quantity the night before and time since last dietary intake where the only 
measures which a significant time effect was detected. Both were found to be 
significantly less for the morning visit than for the other two time points. However, 
neither variable significantly interacted with time of day to affect peak exercise capacity.  
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A study by Bougard et al. [157] specifically investigated the effects of waking time and 
prior dietary intake on the acute response to an exercise test conducted in the early 
morning. A later waking time was associated with a significantly increased exercise 
capacity, VO2, and VCO2 [157]. However, the subjects in Bougard’s study only got 5-6 
hours of sleep the night prior to testing. Having extra time to sleep in the morning may 
have a greater influence on subsequent exercise response in such individuals than in those  
who get a good night sleep [157]. In addition, their subjects were young healthy males of 
either intermediate or evening chronotype. In contrast, subjects from the present study 
reported an average of 7-8 hours of sleep the night prior to testing and were older, 
afflicted with COPD, and of morning or intermediate chronotype. This may explain why 
sleep quantity the night before testing did not play a significant role on exercise 
performance in the current investigation. Bougard and colleagues [157]  also reported a 
significant effect of dietary intake on mean VCO2 and RER values, which were both 
increased after food intake. However, dietary intake did not affect peak exercise capacity, 
which is in line with the results from the present study [157].  
Finally, peak exercise capacity may not have demonstrated statistically significant 
changes across the three testing times in the current study, but consideration of the 
clinical significance of our findings could prove interesting. The minimal clinically 
important difference (MCID) refers to the smallest clinical difference in a measure that 
can either be perceived by the patient or that is believed to be clinically pertinent by 
expert opinion [158]. A study by Sutherland and Make [159] has suggested the MCID for 
maximum exercise capacity in COPD to be within a range of 0.9 to 10.5 watts in patients 
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with severe COPD. This estimate was obtained using both expert opinion and 
distribution-based methods with data from the National Emphysema Treatment Trial 
[159]. In the current study, nine out of the 14 subjects showed a ≥ 10 watts change in 
peak exercise capacity between the different testing times.  These numbers indicate that 
although no overall time effect was detected for peak exercise capacity, a clinically 
significant change may have occurred in a majority of our subjects. Given this 
observation and the fact that changes in exercise capacity across the different testing 
times were heterogeneous within the study sample, it is possible that more complex 
analyses will need to be conducted to determine whether different patterns of response 
exist in this patient population. 
Effect of Time of Day on Pulmonary Function 
The secondary objective of this study was to investigate the effect of time of day on 
pulmonary function in COPD. We hypothesized that pulmonary function would be lowest 
in the morning and highest at noon. This hypothesis was not supported by our results, as 
no overall time effect was found for FEV1, FVC, FEV1/FVC, or IC. 
Pulmonary function is widely acknowledged to have a circadian rhythm in both healthy 
and COPD populations, yet the precise pattern of change remains to be clarified [107, 
113, 116, 160]. In COPD specifically, four different patterns of circadian variations in 
FEV1 have been observed: a morning reduction, an evening reduction, a double dip 
pattern where both a morning and evening reduction is observed, or no change in pattern 
[107, 119, 160]. Certain COPD medications, such as tiotropium –a long-acting 
anticholinergic bronchodilator- have also been shown to shift the timing of FEV1 
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variation [160]. This finding may explain, at least partly, the different patterns reported in 
the literature and highlights the importance of controlling for respiratory medications. In 
the present study, although no overall time effect was found for measures of pulmonary 
function, individual data suggest that different patterns of change may have occurred 
within our study sample, especially for FVC and FEV1/FVC (Figure 7b and 7c). Given 
that subjects were weaned off their COPD medications prior to each exercise test, these 
patterns would likely not be the result of a confounding medication effect. Pattern 
analyses could potentially provide more information regarding the nature of the 
relationship between time of day and pulmonary function. 
 Additionally, timing of the tests may play an important role as the mean daily circadian 
variation in FEV1 has been shown to change by as much as 286 ml when comparing 
maximum and minimum values over a 24-hour period [160].  In order to optimally detect 
circadian changes, six equidistant times must be measured [161]. Therefore, the testing 
times chosen may influence the magnitude of change. In the present study, the three 
testing times were selected to cover the range of when exercise tests are typically 
conducted in clinical practice and not specifically for optimal detection of circadian 
changes. This can be considered as a study limitation; however, the present investigation 
was designed to answer a practical clinical question. 
Using the same approach as for peak exercise capacity, the clinical significance of 
changes seen in pulmonary function was also considered. Although MCIDs for 
measurements of spirometry have yet to be confirmed, some experts have suggested the 
value at 100ml for FEV1 [162]. The reproducibility criteria recommended by current 
64 
 
guidelines for repeated FEV1 measures taken within a single session is 150 ml [41]. 
Although there is no consensus as to the acceptable range for FEV1 measurements 
obtained on different occasions, Herpel et al. [163] have estimated the reproducibility 
between sessions to range from 150 ml to 225 ml [163]. Interestingly, ATS guidelines 
state that successful bronchodilation typically translates into a 200 ml improvement in 
FEV1 [164]. In the present study, nine out 14 patients showed a variability ≥ 100 ml in 
FEV1 between visits, while three subjects showed changes ≥ 150 ml. Furthermore, the 
variability for FVC values was shown to be greater than what was demonstrated for 
FEV1. The reproducibility criteria recommended by current guidelines for repeated FVC 
measures taken within a single session is 150 ml [41]. Herpel et al. [163] suggests that a 
value greater than 325 ml would be reasonable to detect change in FVC. In the present 
study, twelve out 14 subjects showed a variability ≥ 150 ml in FVC between visits, while 
ten out of 14 subjects showed changes ≥ 325 ml. 
Forced expiratory volumes are essential for COPD diagnosis, for disease classification 
and prognosis [162]. However, clinical trials have highlighted the fact that FEV1 and 
FVC may not be the best measures to assess changes in patients’ condition, showing 
weak associations with exertional dyspnea, quality of life or endurance [155, 165]. IC, 
which is a measure of hyperinflation, has been proposed as the link between lung 
function, exercise capacity and symptoms of dyspnea [155, 166]. Circadian rhythms have 
been documented for IC in COPD; more specifically, IC is reportedly lowest in the 
morning [40, 167].  Measures of IC were taken during the course of this study both at rest 
and at peak, yet no overall time effect was found. However, individual data seem to 
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reveal different patterns of change (Figure 8). Further analyses will be needed to support 
this observation. 
Effect of Time of Day on Physiological Measures during Rest and Exercise 
Circadian rhythms have been detected in certain metabolic variables, but how these 
rhythms are influenced under exercise and disease conditions has yet to be determined 
[168]. For the present study, it was hypothesized that metabolic response would be 
highest in the afternoon in COPD patients. This hypothesis was based on findings on 
healthy individuals, in whom resting VO2, VCO2 and VE have been shown to peak in the 
afternoon following peak core body temperature [126]. Our results, however, did not 
support this hypothesis, as no significant variations in resting or peak VO2, VCO2, and VE 
were found across the three testing times. Other researchers have come to similar 
conclusions: discrepancies in methodology, time of day, and study population could 
potentially account for these differences [112, 169].  
Despite the fact that no changes were observed in resting VO2 and VCO2, resting RER - 
which corresponds to the ratio of VCO2 to VO2 – was found to be significantly higher in 
the morning than at the other two time points. This may be due to the influence of last 
dietary intake, which was found to be significantly closer to testing time for the morning 
than for the afternoon visits. The effect of food intake versus a fasted state on RER has 
been studied, and the fasting state was shown to yield a significantly lower RER [170]. 
Therefore, to limit variability and control for this potential confounding factor, a 
standardized intake time could have been set apriori; however, for the morning test, this 
would likely have meant earlier wake times, which could have introduced another bias. It 
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should also be noted that as the subjects in this study had a mean age of 71 years, they 
may have been prescribed other non-respiratory medications requiring food intake.  
The variation seen in resting RER was not duplicated at peak. It is currently unknown 
whether or not variations in resting RER resulting from substrate utilization would persist 
under exercise conditions [171]. Results from the present study suggest that they may not 
persist. 
In other measures, a trend was seen for the effect of testing time on VT. Prior evidence 
has shown that, in expiratory flow-limited individuals, as the absolute value for VT 
increases, EELV tends to increase as well, leading to hyperinflation of the lungs, as IRV 
and IC decreases [42, 172]. These changes would thus take place in a cascade effect, 
where hyperinflation would occur in response to an increase in VT. In the present study, 
VT tended to be higher in the morning than in the afternoon. According to the “cascade 
effect” described above, this should have led to more hyperinflation (i.e. smaller IC) in 
the morning than in the afternoon. The mean IC value was smaller for the morning visit 
than for the afternoon visit, but this time effect was not significant. Furthermore, there 
was no time by state interaction for VT, suggesting that the response to exercise was 
similar across testing times.      
Finally, a trend was observed for the effect of testing time on HR, which tended to 
increase throughout the day. In previous studies, diurnal variations in HR have been 
calculated to fluctuate between 2 and 6 beats per minute [126, 173]. In the current study, 
HR was 3.3 beats per minute greater in the afternoon as compared to the morning. 
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However, when comparing individual data, 10 out of the 14 subjects had changes in HR 
that were greater than or equal to 6 beats per minute across the different times of the day. 
Effect of Time of Day on Symptom Perception 
The final objective of the present investigation was to evaluate the impact of time of day 
on subjects’ perception of dyspnea and leg fatigue at rest and during exercise. It was 
hypothesized that symptoms would be perceived to be greater in the morning. Our results 
indicate that symptoms did increase in response to exercise, as expected, but were not 
affected by testing time.  
In COPD, subjects are often limited by leg fatigue and dyspnea prior to attaining a true 
physiological maximum. Perhaps conducting an endurance test, which could be more 
sensitive to change, would allow for greater variations to be detected [174]. The stimulus 
for perceived symptoms is based on the work achieved; it may be more feasible to 
increase endurance time than to reach a higher work rate on an incremental test [98, 154]. 
Effect Size 
This study is the first of its kind to measure diurnal variations in peak exercise capacity in 
COPD subjects. As such, sample size calculation was based on peak exercise capacity 
variations reported in similar studies conducted in other populations. Furthermore, the 
study was not powered to detect changes in secondary objectives. The negative results 
obtained for overall time effects on exercise capacity and pulmonary function may 
suggest that the study was underpowered. Effect sizes observed in the present study will 
be useful for sample size calculations for future studies investigating diurnal variations in 




The general aim of the present study was to investigate the impact of time of day on the 
acute response to exercise in individuals with COPD. Although no overall time effect was 
found for peak exercise capacity, changes at or beyond the suggested minimal clinically 
important difference were observed in a majority of the subjects. Our results suggest that 
diurnal variations in the acute response to exercise may be heterogeneous among COPD 
patients and may follow more than one pattern. Further analyses will be needed to 
support this observation.  
Given that exercise testing is routinely used in COPD to confirm diagnosis, determine 
prognosis, and evaluate response to treatment, the clinical implications of our findings are 
significant. Latest guidelines recommend that repeated exercise tests be conducted at the 
same time of day to avoid the potential confounding effect of testing time on measured 
outcomes. Results from the present study did not confirm the presence of such a time 
effect in COPD patients, but suggest that caution is warranted. Finally, given the limited 
research conducted to date in the field of chronobiology and COPD, further studies are 








Table 2 - Subject Characteristics*  
 
 
Male/female, n/n  9/5 
Age, yrs 71 ±7 
Height, m 1.70 ± 0.08 
Weight, kg 78.21 ± 14.77 
BMI, kg/m
2
  27±5 
FEV1 , L  1.48± 0.4 
FEV1 ,% pred.  58±13 
FVC,  L  2.83±0.64 
FEV1/FVC ,% 53±11 
Chronotype (morning / intermediate), n/n    9/5 
*Values in mean ± SD 





Table 3 – Changes in mean physiological response from rest to peak across three times 
of the day* 
Physiological Measure 8:00 12:00 16:00 
VO2 rest (ml/min/kg) 3.6 ± 0.6 3.6 ± 1.2 3.4 ± 0.8 
VO2, peak (ml/min/kg) 13.7 ± 51.4 14.4 ± 79.9 14.1 ± 64 
VCO2 rest (ml/min) 250.2 ± 51.4 234.1 ± 79.9 224.3 ± 64 
VCO2, peak (ml/min) 1057.6 ± 281.7 1102.9 ± 275.8 1086.2 ± 289.5 
RER rest 0.9 ± 0.1
**
 0.8 ± 0.1 0.8 ± 0.1 
RER peak 1.0 ± 0.1 1.0 ± 0.1 1.0 ± 0.1 
VE rest (L) 11.8 ± 2.0 11.6 ± 2.7 11.3 ± 3.1 
VE peak, (L) 40.6 ± 8.8 41.8 ± 7.4 42.0 ± 8.9 
RR rest, (L/min)  16.4 ± 5.3 18 ± 5.1 18.4 ± 3.2 
RR peak, (L/min)  32.4 ± 5.8 32.2 ± 5.9 33.2 ± 4.8 
VT rest, (L) 0.9 ± 0.4 0.8 ± 0.4 0.7 ± 0.3 
VT peak, (L) 1.3 ± 0.2 1.3 ± 0.3 1.3 ± 0.3 
SpO2 rest, (%) 97 ± 1.1 97 ± 1.4 97 ± 1.3 
SpO2 rest, (%) 95 ±1.4 95 ± 1.6 95 ± 1.6 
BP systolic rest, (mmHg) 114 ± 23.1 121 ± 14.7 121 ± 22 
BP systolic peak, (mmHg) 176 ± 26.6 183 ± 27.1 173 ± 20.4 
BP diastolic rest, (mmHg) 75 ± 7.2 74 ± 7.4 77 ± 10.6 
BP diastolic peak, (mmHg) 80 ± 12.9 78 ± 9 81 ± 12.7 
*Values are mean ± SD, 
**
 Significantly different from other two time points, p < 0.05. 
VO2: oxygen consumption, VCO2: carbon dioxide production, RER: respiratory exchange ratio, VE: minute 




Table 4 – Symptoms of perceived dyspnea and leg fatigue as measured by the modified 
10 point Borg scale across three times of day* 
 
Symptoms 8:00 12:00 16:00 
Dyspnea rest 0.36 ± 0.6 0.21 ± 0.4 0.14 ± 0.4 
Dyspnea peak 6 ± 2.4 6 ± 2.3 6 ± 1.9 
Leg fatigue rest 0.14 ± 0.4 0 ± 0 0.07 ± 0.3 
Leg fatigue peak 6 ± 2.3 6 ± 1.9 6 ± 2.2 




Figure 4 – Study timeline 
 






Figure 5 - Individual data and group means (horizontal bars) for peak exercise capacity 







Figure 6 – Interactive effect of time of day and chronotype (Panel A), age (Panel B), sex (Panel C), and BMI (Panel D) on 
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Figure 7 – Individual data and group means (horizontal bars) for FEV1 (Panel A), FVC 










Figure 8 – Individual data and group means (horizontal bars) for inspiratory capacity 
measures obtained at rest (Panel A) and at peak exercise (Panel B) across the three 









1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the 
diagnosis, management, and prevention of chronic obstructive pulmonary 
disease. 2010: p. 117. 
2. O'Donnell, D.E., et al., Canadian Thoracic Society recommendations for 
management of chronic obstructive pulmonary disease - 2008 update - highlights 
for primary care. Can Respir J, 2008. 15 Suppl A: p. 1A-8A. 
3. Ries, A.L., et al., Pulmonary Rehabilitation: Joint ACCP/AACVPR Evidence-
Based Clinical Practice Guidelines. Chest, 2007. 131(5 Suppl): p. 4S-42S. 
4. Bryanton, et al., Respiratory Disease in Canada. Health Canada, 2001: p. p.118. 
5. Public Health Agency of Canada, Life and Breath: Respiratory Disease in 
Canada. 2007. 
6. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the 
Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary 
Disease. 2008. 
7. Devereux, G., ABC of chronic obstructive pulmonary disease. Definition, 
epidemiology, and risk factors. BMJ, 2006. 332(7550): p. 1142-4. 
8. Celli, B.R. and W. MacNee, Standards for the diagnosis and treatment of patients 
with COPD: a summary of the ATS/ERS position paper. Eur Respir J, 2004. 
23(6): p. 932-46. 
9. O'Donnell, D.E., et al., Canadian Thoracic Society recommendations for 
management of chronic obstructive pulmonary disease--2003. Can Respir J, 
2003. 10 Suppl A: p. 11A-65A. 
10. Pauwels, R.A. and K.F. Rabe, Burden and clinical features of chronic obstructive 
pulmonary disease (COPD). Lancet, 2004. 364(9434): p. 613-20. 
11. O'Donnell, D.E., S.M. Revill, and K.A. Webb, Dynamic hyperinflation and 
exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit 
Care Med, 2001. 164(5): p. 770-7. 
12. Jansson, S.A., et al., Costs of COPD in Sweden according to disease severity. 
Chest, 2002. 122(6): p. 1994-2002. 
13. O'Donnell, D.E., et al., Canadian Thoracic Society recommendations for 
management of chronic obstructive pulmonary disease - 2007 update. Can 
Respir J, 2007. 14 Suppl B: p. 5B-32B. 
14. Fletcher, C. and R. Peto, The natural history of chronic airflow obstruction. Br 
Med J, 1977. 1(6077): p. 1645-8. 
15. Burrows, B., et al., Quantitative relationships between cigarette smoking and 
ventilatory function. Am Rev Respir Dis, 1977. 115(2): p. 195-205. 
16. Stockley, R.A., D. Mannino, and P.J. Barnes, Burden and pathogenesis of 
chronic obstructive pulmonary disease. Proc Am Thorac Soc, 2009. 6(6): p. 524-
6. 
17. Balmes, J., et al., American Thoracic Society Statement: Occupational 
contribution to the burden of airway disease. Am J Respir Crit Care Med, 2003. 
167(5): p. 787-97. 
18. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the 




19. Abbey, D.E., et al., Long-term particulate and other air pollutants and lung 
function in nonsmokers. Am J Respir Crit Care Med, 1998. 158(1): p. 289-98. 
20. Shi, W., S. Bellusci, and D. Warburton, Lung development and adult lung 
diseases. Chest, 2007. 132(2): p. 651-6. 
21. Stern, D.A., et al., Poor airway function in early infancy and lung function by age 
22 years: a non-selective longitudinal cohort study. Lancet, 2007. 370(9589): p. 
758-64. 
22. Maciewicz, R.A., D. Warburton, and S.I. Rennard, Can increased understanding 
of the role of lung development and aging drive new advances in chronic 
obstructive pulmonary disease? Proc Am Thorac Soc, 2009. 6(7): p. 614-7. 
23. Anthonisen, N.R., J.E. Connett, and R.P. Murray, Smoking and lung function of 
Lung Health Study participants after 11 years. Am J Respir Crit Care Med, 2002. 
166(5): p. 675-9. 
24. Aw, D., A.B. Silva, and D.B. Palmer, Immunosenescence: emerging challenges 
for an ageing population. Immunology, 2007. 120(4): p. 435-46. 
25. Retamales, I., et al., Amplification of inflammation in emphysema and its 
association with latent adenoviral infection. Am J Respir Crit Care Med, 2001. 
164(3): p. 469-73. 
26. Sethi, S., et al., Airway inflammation and bronchial bacterial colonization in 
chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2006. 
173(9): p. 991-8. 
27. Taylor, B. and J. Wadsworth, Maternal smoking during pregnancy and lower 
respiratory tract illness in early life. Arch Dis Child, 1987. 62(8): p. 786-91. 
28. MacNee, W. and I. Rahman, Is oxidative stress central to the pathogenesis of 
chronic obstructive pulmonary disease? Trends Mol Med, 2001. 7(2): p. 55-62. 
29. Hogg, J.C., Lung structure and function in COPD. Int J Tuberc Lung Dis, 2008. 
12(5): p. 467-79. 
30. Rutgers, S.R., et al., Ongoing airway inflammation in patients with COPD who do 
not currently smoke. Thorax, 2000. 55(1): p. 12-8. 
31. Hogg, J.C., et al., The nature of small-airway obstruction in chronic obstructive 
pulmonary disease. N Engl J Med, 2004. 350(26): p. 2645-53. 
32. Hogg, J.C. and W. Timens, The pathology of chronic obstructive pulmonary 
disease. Annu Rev Pathol, 2009. 4: p. 435-59. 
33. Maestrelli, P., et al., Remodeling in response to infection and injury. Airway 
inflammation and hypersecretion of mucus in smoking subjects with chronic 
obstructive pulmonary disease. Am J Respir Crit Care Med, 2001. 164(10 Pt 2): 
p. S76-80. 
34. Taylor, J.D., COPD and the response of the lung to tobacco smoke exposure. 
Pulm Pharmacol Ther, 2010. 
35. Atherton, H.C., G. Jones, and H. Danahay, IL-13-induced changes in the goblet 
cell density of human bronchial epithelial cell cultures: MAP kinase and 
phosphatidylinositol 3-kinase regulation. Am J Physiol Lung Cell Mol Physiol, 
2003. 285(3): p. L730-9. 
36. Rennard, S.I., Inflammation and repair processes in chronic obstructive 
pulmonary disease. Am J Respir Crit Care Med, 1999. 160(5 Pt 2): p. S12-6. 
37. Ind, P.W., COPD disease progression and airway inflammation: uncoupled by 
smoking cessation. Eur Respir J, 2005. 26(5): p. 764-6. 
38. Baraldo, S., et al., Neutrophilic infiltration within the airway smooth muscle in 
patients with COPD. Thorax, 2004. 59(4): p. 308-12. 
 79 
 
39. Lambert, R.K., et al., Functional significance of increased airway smooth muscle 
in asthma and COPD. J Appl Physiol, 1993. 74(6): p. 2771-81. 
40. Ferguson, G.T., Why does the lung hyperinflate? Proc Am Thorac Soc, 2006. 
3(2): p. 176-9. 
41. Miller, M.R., et al., Standardisation of spirometry. Eur Respir J, 2005. 26(2): p. 
319-38. 
42. ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit 
Care Med, 2003. 167(2): p. 211-77. 
43. O'Donnell, D.E., M. Lam, and K.A. Webb, Measurement of symptoms, lung 
hyperinflation, and endurance during exercise in chronic obstructive pulmonary 
disease. Am J Respir Crit Care Med, 1998. 158(5 Pt 1): p. 1557-65. 
44. Cosio, M., et al., The relations between structural changes in small airways and 
pulmonary-function tests. N Engl J Med, 1978. 298(23): p. 1277-81. 
45. MacIntyre, N.R., Mechanisms of functional loss in patients with chronic lung 
disease. Respir Care, 2008. 53(9): p. 1177-84. 
46. Panos, R.J. and W. Eschenbacher, Exertional desaturation in patients with 
chronic obstructive pulmonary disease. COPD, 2009. 6(6): p. 478-87. 
47. Wagner, P.D., et al., Continuous distributions of ventilation-perfusion ratios in 
normal subjects breathing air and 100 per cent O2. J Clin Invest, 1974. 54(1): p. 
54-68. 
48. West, J.B., State of the art: ventilation-perfusion relationships. Am Rev Respir 
Dis, 1977. 116(5): p. 919-43. 
49. Engelen, M.P., et al., Contribution of the respiratory muscles to the lactic acidosis 
of heavy exercise in COPD. Chest, 1995. 108(5): p. 1246-51. 
50. Nici, L., et al., American Thoracic Society/European Respiratory Society 
statement on pulmonary rehabilitation. Am J Respir Crit Care Med, 2006. 
173(12): p. 1390-413. 
51. Similowski, T., et al., Contractile properties of the human diaphragm during 
chronic hyperinflation. N Engl J Med, 1991. 325(13): p. 917-23. 
52. McKenzie, D.K., J.E. Butler, and S.C. Gandevia, Respiratory muscle function and 
activation in chronic obstructive pulmonary disease. J Appl Physiol, 2009. 107(2): 
p. 621-9. 
53. Pepin, V., F. Maltais, and Y. Lacasse, Goals of Treatments and Measurement of 
Their Efficacy: From Clinical Trials to Real World Practice. , in Clinical 
Management of Chronic Obstructive Pulmonary Disease, H.G. Rennard SI, 
Rodriguez-Roisin R, Roche N, Editor. 2007, Taylor & Francis Group.: New York, 
NY. p. 239-261. 
54. Levine, S., et al., Cellular adaptations in the diaphragm in chronic obstructive 
pulmonary disease. N Engl J Med, 1997. 337(25): p. 1799-806. 
55. Orozco-Levi, M., Structure and function of the respiratory muscles in patients 
with COPD: impairment or adaptation? Eur Respir J Suppl, 2003. 46: p. 41s-51s. 
56. Maltais, F., Skeletal muscles in chronic airflow obstruction: why bother? Am J 
Respir Crit Care Med, 2003. 168(8): p. 916-7. 
57. Casaburi, R., et al., Reductions in exercise lactic acidosis and ventilation as a 
result of exercise training in patients with obstructive lung disease. Am Rev 
Respir Dis, 1991. 143(1): p. 9-18. 
58. Pepin, V., et al., Exercise capacity in chronic obstructive pulmonary disease: 
mechanisms of limitation. COPD, 2007. 4(3): p. 195-204. 
 80 
 
59. Oga, T., et al., Analysis of the factors related to mortality in chronic obstructive 
pulmonary disease: role of exercise capacity and health status. Am J Respir Crit 
Care Med, 2003. 167(4): p. 544-9. 
60. Killian, K.J., et al., Exercise capacity and ventilatory, circulatory, and symptom 
limitation in patients with chronic airflow limitation. Am Rev Respir Dis, 1992. 
146(4): p. 935-40. 
61. Pepin, V., et al., Walking versus cycling: sensitivity to bronchodilation in chronic 
obstructive pulmonary disease. Am J Respir Crit Care Med, 2005. 172(12): p. 
1517-22. 
62. Calverley, P.M. and N.G. Koulouris, Flow limitation and dynamic hyperinflation: 
key concepts in modern respiratory physiology. Eur Respir J, 2005. 25(1): p. 186-
99. 
63. Hyatt, R.E., Expiratory flow limitation. J Appl Physiol, 1983. 55(1 Pt 1): p. 1-7. 
64. O'Donnell, D.E., et al., Pathophysiology of dyspnea in chronic obstructive 
pulmonary disease: a roundtable. Proc Am Thorac Soc, 2007. 4(2): p. 145-68. 
65. Maltais, F., et al., Improvements in symptom-limited exercise performance over 8 
h with once-daily tiotropium in patients with COPD. Chest, 2005. 128(3): p. 1168-
78. 
66. Saey, D., et al., Contractile leg fatigue after cycle exercise: a factor limiting 
exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit 
Care Med, 2003. 168(4): p. 425-30. 
67. Maltais, F., et al., Metabolic and hemodynamic responses of lower limb during 
exercise in patients with COPD. J Appl Physiol, 1998. 84(5): p. 1573-80. 
68. Barbera, J.A., V.I. Peinado, and S. Santos, Pulmonary hypertension in chronic 
obstructive pulmonary disease. Eur Respir J, 2003. 21(5): p. 892-905. 
69. Franciosi, L.G., et al., Markers of exacerbation severity in chronic obstructive 
pulmonary disease. Respir Res, 2006. 7: p. 74. 
70. Wedzicha, J.A. and G.C. Donaldson, Exacerbations of chronic obstructive 
pulmonary disease. Respir Care, 2003. 48(12): p. 1204-13; discussion 1213-5. 
71. Seemungal, T.A., Effect of exacerbation on quality of life in patients with chronic 
obstructive pulmonary disease. Am J Respir Crit Care Med, 1998. 157: p. 1418-
1422. 
72. Seemungal, T.A., et al., Time course and recovery of exacerbations in patients 
with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2000. 
161(5): p. 1608-13. 
73. Davies, L., R.M. Angus, and P.M. Calverley, Oral corticosteroids in patients 
admitted to hospital with exacerbations of chronic obstructive pulmonary disease: 
a prospective randomised controlled trial. Lancet, 1999. 354(9177): p. 456-60. 
74. Niewoehner, D.E., et al., Effect of systemic glucocorticoids on exacerbations of 
chronic obstructive pulmonary disease. Department of Veterans Affairs 
Cooperative Study Group. N Engl J Med, 1999. 340(25): p. 1941-7. 
75. Thompson, W.H., et al., Controlled trial of oral prednisone in outpatients with 
acute COPD exacerbation. Am J Respir Crit Care Med, 1996. 154(2 Pt 1): p. 
407-12. 
76. Anthonisen, N.R., et al., Effects of smoking intervention and the use of an inhaled 
anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health 
Study. JAMA, 1994. 272(19): p. 1497-505. 
 81 
 
77. Zhou, Y., et al., Positive benefits of theophylline in a randomized, double-blind, 
parallel-group, placebo-controlled study of low-dose, slow-release theophylline in 
the treatment of COPD for 1 year. Respirology, 2006. 11(5): p. 603-10. 
78. Belman, M.J., W.C. Botnick, and J.W. Shin, Inhaled bronchodilators reduce 
dynamic hyperinflation during exercise in patients with chronic obstructive 
pulmonary disease. Am J Respir Crit Care Med, 1996. 153(3): p. 967-75. 
79. Troosters, T., et al., Pulmonary rehabilitation in chronic obstructive pulmonary 
disease. Am J Respir Crit Care Med, 2005. 172(1): p. 19-38. 
80. Lacasse, Y., et al., Pulmonary rehabilitation for chronic obstructive pulmonary 
disease. Cochrane Database Syst Rev, 2002(3): p. CD003793. 
81. Maltais, F., et al., Skeletal muscle adaptation to endurance training in patients 
with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 1996. 
154(2 Pt 1): p. 442-7. 
82. Emery, C.F., et al., Psychological outcomes of a pulmonary rehabilitation 
program. Chest, 1991. 100(3): p. 613-7. 
83. Emery, C.F., et al., Acute effects of exercise on cognition in patients with chronic 
obstructive pulmonary disease. Am J Respir Crit Care Med, 2001. 164(9): p. 
1624-7. 
84. Lacasse, Y., et al., Pulmonary rehabilitation for chronic obstructive pulmonary 
disease. Cochrane Database Syst Rev, 2006(4): p. CD003793. 
85. Martinez, F.J., et al., Lung-volume reduction improves dyspnea, dynamic 
hyperinflation, and respiratory muscle function. Am J Respir Crit Care Med, 1997. 
155(6): p. 1984-90. 
86. Martinez, F.J. and A. Chang, Surgical therapy for chronic obstructive pulmonary 
disease. Semin Respir Crit Care Med, 2005. 26(2): p. 167-91. 
87. Fishman, A., et al., A randomized trial comparing lung-volume-reduction surgery 
with medical therapy for severe emphysema. N Engl J Med, 2003. 348(21): p. 
2059-73. 
88. Chan-Thim, E., et al., Pulmonary Rehabilitation as an Aid to Smoking cessation: 
A Preliminary Study. CHEST, 2009. 136: p. 56s-g. 
89. Kesten, S. and K.R. Chapman, Physician perceptions and management of 
COPD. Chest, 1993. 104(1): p. 254-8. 
90. Loveridge, B., et al., Alteration in breathing pattern with progression of chronic 
obstructive pulmonary disease. Am Rev Respir Dis, 1986. 134(5): p. 930-4. 
91. Nici, L., Mechanisms and measures of exercise intolerance in chronic obstructive 
pulmonary disease. Clin Chest Med, 2000. 21(4): p. 693-704. 
92. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care 
Med, 2002. 166(1): p. 111-7. 
93. Gallagher, C.G., Exercise limitation and clinical exercise testing in chronic 
obstructive pulmonary disease. Clin Chest Med, 1994. 15(2): p. 305-26. 
94. Weisman, I.M. and R.J. Zeballos, An integrated approach to the interpretation of 
cardiopulmonary exercise testing. Clin Chest Med, 1994. 15(2): p. 421-45. 
95. Sue, D.Y. and K. Wasserman, Impact of integrative cardiopulmonary exercise 
testing on clinical decision making. Chest, 1991. 99(4): p. 981-92. 
96. Revill, S.M., et al., The endurance shuttle walk: a new field test for the 
assessment of endurance capacity in chronic obstructive pulmonary disease. 
Thorax, 1999. 54(3): p. 213-22. 
97. Oga, T., et al., The effects of oxitropium bromide on exercise performance in 
patients with stable chronic obstructive pulmonary disease. A comparison of 
 82 
 
three different exercise tests. Am J Respir Crit Care Med, 2000. 161(6): p. 1897-
901. 
98. Ong, K.C., et al., Comparison of different exercise tests in assessing outcomes of 
pulmonary rehabilitation. Respir Care, 2004. 49(12): p. 1498-503. 
99. Eaton, T., et al., The endurance shuttle walking test: a responsive measure in 
pulmonary rehabilitation for COPD patients. Chron Respir Dis, 2006. 3(1): p. 3-9. 
100. Skeletal muscle dysfunction in chronic obstructive pulmonary disease. A 
statement of the American Thoracic Society and European Respiratory Society. 
Am J Respir Crit Care Med, 1999. 159(4 Pt 2): p. S1-40. 
101. Noseda, A., et al., Lung function, maximum and submaximum exercise testing in 
COPD patients: reproducibility over a long interval. Lung, 1989. 167(4): p. 247-
57. 
102. Marciniuk, D.D., R.E. Watts, and C.G. Gallagher, Reproducibility of incremental 
maximal cycle ergometer testing in patients with restrictive lung disease. Thorax, 
1993. 48(9): p. 894-8. 
103. Garrard, C.S. and C. Emmons, The reproducibility of the respiratory responses to 
maximum exercise. Respiration, 1986. 49(2): p. 94-100. 
104. Guyatt, G.H., et al., Effect of encouragement on walking test performance. 
Thorax, 1984. 39(11): p. 818-22. 
105. Atkinson, G. and T. Reilly, Circadian variation in sports performance. Sports 
Med, 1996. 21(4): p. 292-312. 
106. Reilly, T., Human circadian rhythms and exercise. Crit Rev Biomed Eng, 1990. 
18(3): p. 165-80. 
107. Medarov, B.I., V.A. Pavlov, and L. Rossoff, Diurnal variations in human 
pulmonary function. Int J Clin Exp Med, 2008. 1(3): p. 267-73. 
108. Klerman, E.B., Clinical aspects of human circadian rhythms. J Biol Rhythms, 
2005. 20(4): p. 375-86. 
109. Spengler, C.M. and S.A. Shea, Endogenous circadian rhythm of pulmonary 
function in healthy humans. Am J Respir Crit Care Med, 2000. 162(3 Pt 1): p. 
1038-46. 
110. Waterhouse, J., et al., The circadian rhythm of core temperature: origin and 
some implications for exercise performance. Chronobiol Int, 2005. 22(2): p. 207-
25. 
111. Mills, J.N., Human circadian rhythms. Physiol Rev, 1966. 46(1): p. 128-71. 
112. Brisswalter, J., et al., Morning-to-evening differences in oxygen uptake kinetics in 
short-duration cycling exercise. Chronobiol Int, 2007. 24(3): p. 495-506. 
113. Hetzel, M.R., The pulmonary clock. Thorax, 1981. 36(7): p. 481-6. 
114. Lewinsohn, H.C., L.H. Capel, and J. Smart, Changes in forced expiratory 
volumes throughout the day. Br Med J, 1960. 1(5171): p. 462-4. 
115. Petty, T.L., Circadian variations in chronic asthma and chronic obstructive 
pulmonary disease. Am J Med, 1988. 85(1B): p. 21-3. 
116. Dawkins, K.D. and M.F. Muers, Diurnal variation in airflow obstruction in chronic 
bronchitis. Thorax, 1981. 36(8): p. 618-21. 
117. Borsboom, G.J., et al., Diurnal variation in lung function in subgroups from two 
Dutch populations: consequences for longitudinal analysis. Am J Respir Crit Care 
Med, 1999. 159(4 Pt 1): p. 1163-71. 
118. Gaultier, C., A. Reinberg, and F. Girard, Circadian rhythms in lung resistance and 
dynamic lung compliance of healthy children. Effects of two bronchodilators. 
Respir Physiol, 1977. 31(2): p. 169-82. 
 83 
 
119. Teramoto, S., et al., Influence of age on diurnal variability in measurements of 
spirometric indices and respiratory pressures. J Asthma, 1999. 36(6): p. 487-92. 
120. Soutar, C.A., et al., Nocturnal and morning asthma. Relationship to plasma 
corticosteroids and response to cortisol infusion. Thorax, 1975. 30(4): p. 436-40. 
121. Cochrane, G.M., B.A. Webber, and S.W. Clarke, Effects of sputum on pulmonary 
function. Br Med J, 1977. 2(6096): p. 1181-3. 
122. Cinkotai, F.F. and M.L. Thomson, Diurnal variation in pulmonary diffusing 
capacity for carbon monoxide. J Appl Physiol, 1966. 21(2): p. 539-42. 
123. Burioka, N., et al., Circadian Rhythms of the Indices in the Diffusing Function of 
the Lung in Healthy Men. Yonago Acta medica, 1999. 42: p. 182-192. 
124. Saito, S., N. Burioka, and E. Hoshino, Circadian variation of the lung elastic recoil 
pressure in healthy male non-smokers. Yonago Igaku Zasshi, 1996. 47: p. 130-
139. 
125. Reilly, T. and G.A. Brooks, Investigation of circadian rhythms in metabolic 
responses to exercise. Ergonomics, 1982. 25(11): p. 1093-107. 
126. Reilly, T. and G.A. Brooks, Selective persistence of circadian rhythms in 
physiological responses to exercise. Chronobiol Int, 1990. 7(1): p. 59-67. 
127. Minors, D. and J. Waterhouse, Circadian rhythms and the human. 1981, London: 
John Wright. 332. 
128. Hill, D.W., et al., Diurnal variations in responses to exercise of "morning types" 
and "evening types". J Sports Med Phys Fitness, 1988. 28(3): p. 213-9. 
129. Myers, J., et al., Effect of sampling on variability and plateau in oxygen uptake. J 
Appl Physiol, 1990. 68(1): p. 404-10. 
130. Myers, J., et al., Can maximal cardiopulmonary capacity be recognized by a 
plateau in oxygen uptake? Chest, 1989. 96(6): p. 1312-6. 
131. Noakes, T.D., Maximal oxygen uptake: "classical" versus "contemporary" 
viewpoints: a rebuttal. Med Sci Sports Exerc, 1998. 30(9): p. 1381-98. 
132. Aldemir, H., et al., A comparison of the immediate effects of moderate exercise in 
the late morning and late afternoon on core temperature and cutaneous 
thermoregulatory mechanisms. Chronobiol Int, 2000. 17(2): p. 197-207. 
133. Waterhouse, J., et al., Thermoregulation during mild exercise at different 
circadian times. Chronobiol Int, 2004. 21(2): p. 253-75. 
134. Dufour Doiron, M., D. Prud'homme, and P. Boulay, Time-of-day variation in 
cardiovascular response to maximal exercise testing in coronary heart disease 
patients taking a beta-blocker. Appl Physiol Nutr Metab, 2007. 32(4): p. 664-9. 
135. de Vries, R.J.M., The Outcome of Exercise Tolerance Testing is Dependent on 
the Time of the Day. Annals of Noninvasive Electrocardiology, 1997. 2(4): p. 326-
330. 
136. Manthena, P. and P.C. Zee, Neurobiology of circadian rhythm sleep disorders. 
Curr Neurol Neurosci Rep, 2006. 6(2): p. 163-8. 
137. Phillips, B.A., K.R. Cooper, and T.V. Burke, The effect of sleep loss on breathing 
in chronic obstructive pulmonary disease. Chest, 1987. 91(1): p. 29-32. 
138. Rhind, G.B., et al., Sustained release choline theophyllinate in nocturnal asthma. 
Br Med J (Clin Res Ed), 1985. 291(6509): p. 1605-7. 
139. Reishtein, J.L., Relationship between symptoms and functional performance in 
COPD. Res Nurs Health, 2005. 28(1): p. 39-47. 
140. Czeisler, C.A., et al., Stability, precision, and near-24-hour period of the human 
circadian pacemaker. Science, 1999. 284(5423): p. 2177-81. 
 84 
 
141. Tsai, C.L., B.E. Brenner, and C.A. Camargo, Jr., Circadian-rhythm differences 
among emergency department patients with chronic obstructive pulmonary 
disease exacerbation. Chronobiol Int, 2007. 24(4): p. 699-713. 
142. Smolensky, M.H. and E. Haus, Circadian rhythms and clinical medicine with 
applications to hypertension. Am J Hypertens, 2001. 14(9 Pt 2): p. 280S-290S. 
143. Goulet, G., et al., Daily light exposure in morning-type and evening-type 
individuals. J Biol Rhythms, 2007. 22(2): p. 151-8. 
144. Akerstedt, T. and L. Torsvall, Shift work. Shift-dependent well-being and 
individual differences. Ergonomics, 1981. 24(4): p. 265-73. 
145. Monk, T.H., Sleep disorders in the elderly. Circadian rhythm. Clin Geriatr Med, 
1989. 5(2): p. 331-46. 
146. Atkinson, G., et al., A comparison of circadian rhythms in work performance 
between physically active and inactive subjects. Ergonomics, 1993. 36(1-3): p. 
273-81. 
147. Wever, R.A., Phase shifts of human circadian rhythms due to shifts of artificial 
Zeitgebers. Chronobiologia, 1980. 7(3): p. 303-27. 
148. Horne, J.A. and O. Ostberg, A self-assessment questionnaire to determine 
morningness-eveningness in human circadian rhythms. Int J Chronobiol, 1976. 
4(2): p. 97-110. 
149. Horne, J.A., C.G. Brass, and A.N. Pettitt, Ciradian performance differences 
between morning and evening "types". Ergonomics, 1980. 23(1): p. 29-36. 
150. Monk, T.H., et al., The Pittsburgh Sleep Diary. J Sleep Res, 1994. 3(2): p. 111-
120. 
151. Quanjer, P.H., et al., Lung volumes and forced ventilatory flows. Report Working 
Party Standardization of Lung Function Tests, European Community for Steel 
and Coal. Official Statement of the European Respiratory Society. Eur Respir J 
Suppl, 1993. 16: p. 5-40. 
152. Jones, N.L., et al., Normal standards for an incremental progressive cycle 
ergometer test. Am Rev Respir Dis, 1985. 131(5): p. 700-8. 
153. Borg, G.A., Psychophysical bases of perceived exertion. Med Sci Sports Exerc, 
1982. 14(5): p. 377-81. 
154. Mahler, D.A., Pulmonary rehabilitation. Chest, 1998. 113(4 Suppl): p. 263S-
268S. 
155. O'Donnell, D.E., et al., Effect of salmeterol on the ventilatory response to 
exercise in chronic obstructive pulmonary disease. Eur Respir J, 2004. 24(1): p. 
86-94. 
156. Oga, T., et al., Exercise responses during endurance testing at different 
intensities in patients with COPD. Respir Med, 2004. 98(6): p. 515-21. 
157. Bougard, C., et al., Effects of waking time and breakfast intake prior to evaluation 
of physical performance in the early morning. Chronobiol Int, 2009. 26(2): p. 307-
23. 
158. Make, B., R. Casaburi, and N.K. Leidy, Interpreting results from clinical trials: 
understanding minimal clinically important differences in COPD outcomes. 
COPD, 2005. 2(1): p. 1-5. 
159. Sutherland, E.R. and B.J. Make, Maximum exercise as an outcome in COPD: 
minimal clinically important difference. COPD, 2005. 2(1): p. 137-41. 
160. Calverley, P.M., et al., Effect of tiotropium bromide on circadian variation in 




161. Nelson, W., et al., Methods for cosinor-rhythmometry. Chronobiologia, 1979. 
6(4): p. 305-23. 
162. Donohue, J.F., Minimal clinically important differences in COPD lung function. 
COPD, 2005. 2(1): p. 111-24. 
163. Herpel, L.B., et al., Variability of spirometry in chronic obstructive pulmonary 
disease: results from two clinical trials. Am J Respir Crit Care Med, 2006. 
173(10): p. 1106-13. 
164. Pellegrino, R., et al., Interpretative strategies for lung function tests. Eur Respir J, 
2005. 26(5): p. 948-68. 
165. Kaplan, R.M., et al., Measurement of health-related quality of life in the national 
emphysema treatment trial. Chest, 2004. 126(3): p. 781-9. 
166. Cooper, C.B., Airflow obstruction and exercise. Respir Med, 2009. 103(3): p. 
325-34. 
167. van Noord, J.A., et al., Effects of tiotropium with and without formoterol on airflow 
obstruction and resting hyperinflation in patients with COPD. Chest, 2006. 
129(3): p. 509-17. 
168. Mortola, J.P., Breathing around the clock: an overview of the circadian pattern of 
respiration. Eur J Appl Physiol, 2004. 91(2-3): p. 119-29. 
169. Deschenes, M.R., et al., Biorhythmic influences on functional capacity of human 
muscle and physiological responses. Med Sci Sports Exerc, 1998. 30(9): p. 
1399-407. 
170. Bergman, B.C. and G.A. Brooks, Respiratory gas-exchange ratios during graded 
exercise in fed and fasted trained and untrained men. J Appl Physiol, 1999. 
86(2): p. 479-87. 
171. Goedecke, J.H., et al., Determinants of the variability in respiratory exchange 
ratio at rest and during exercise in trained athletes. Am J Physiol Endocrinol 
Metab, 2000. 279(6): p. E1325-34. 
172. Tantucci, C. and V. Grassi, Flow limitation: an overview. Monaldi Arch Chest Dis, 
1999. 54(4): p. 353-7. 
173. Reilly, T., G. Robinson, and D.S. Minors, Some circulatory responses to exercise 
at different times of day. Med Sci Sports Exerc, 1984. 16(5): p. 477-82. 
174. Reilly, T. and R. Garrett, Investigation of diurnal variation in sustained exercise 















         
 
         
 
         
 
         
 
         
 
Étude des variations diurnes de la tolérance 
à l’effort dans la maladie pulmonaire 
obstructive chronique 
 
        
 
        
 
Carnet de suivi 
        
 
        
 
        
 
  








Date de fin:       
  
 
         
 
  






 514-338-2222 post 3944  
 
 
         
 
         
 
         
 
         
 
         
 
         
 
  












4e visite:       Hr:   
 
 




















































chaque visite = 2h 
Procédures: Formulaire de consentement Journal alimentaire 
Évaluation des fonctions 
pulmonaires 
  Questionnaire de chronotype Prise des médicaments Épreuve maximale sur vélo 
  Questionnaire d’humeur Questionnaire du matin, midi et soir   
  Évaluation des fonctions pulmonaires Questionnaire d’humeur    
  
Familiarisation avec les épreuves 
d'effort 
Actigraphie   
  
Remise et explication du carnet de 
suivi 
    
Compensation: un versement de $50 à la fin de la 4 ème visite du protocole 






















À suivre avant chaque épreuve d’effort 
 
 
1- Évitez de manger un repas copieux dans les 3 heures précédant l’épreuve 
d’effort. Limitez-vous à une collation. 
 
2- Évitez de boire de l’alcool ou tout breuvage avec caféine (café, thé ou 
boisson gazeuse) 3 heures avant l’épreuve d’effort. 
 
3- Évitez de fumer 3 heures avant l’épreuve d’effort. 
 
4- Évitez de porter du vernis à l’ongle 
 
5- Soyez reposé(e), évitez de faire de l’exercice le jour de l’épreuve d’effort.  
 
6- Portez des vêtements souples et confortables et des chaussures de sport. 
 
7- Il est possible que vous soyez fatigué(e) après l’évaluation; au besoin, 
prévoyez que quelqu’un vienne vous chercher et vous raccompagne à la 
maison. 
 
8- Buvez beaucoup (préférablement de l’eau) dans les 24 heures précédant 
l’évaluation pour vous assurer d’être bien hydraté(e). 
 
9- Si vous êtes diabétique, apportez votre glucomètre et une collation. 
 
10- Apportez votre carnet de suivi à chaque visite du protocole. 
 
11- Apportez vos médicaments "de secours". 
 









Visite 2 : 
Date : ___________________ 
 







Visite 3 : 
Date : ___________________ 
 







Visite 4 : 
Date : _____________________ 
 









Consignes pour remplir le carnet 
 
 Chaque jour, vous avez 3 questionnaires à remplir: 
1. Questionnaires du matin: à remplir après le déjeuner 
2. Questionnaires du midi: à remplir après le dîner 
3. Questionnaires du soir: à remplir après le souper 
 
 Indiquez, en haut de la page, l’heure à laquelle vous remplissez chaque 
questionnaire. 
 
 Le carnet doit être rempli pendant 7 journées consecutives du 
_______________ au ______________ inclusivement. 
 
 Veuillez répondre à toutes les questions, il y a plusieurs parties à remplir : 
 
Matin : 
Description de l’alimentation 
Heures de la prise de médicaments 
Questions sur le sommeil (7 questions) 
Questionnaire sur l’humeur (6 questions) 
 
Midi : 
Description de l’alimentation 
Heures de la prise de médicaments 
Questionnaire sur l’humeur (6 questions) 
 
Soir : 
Description de l’alimentation 
Heures de la prise de médicaments 
Questions sur vos activités (3 questions) 
Questionnaire sur l’humeur (6 questions) 
 
Si vous avez d’autres commentaires ou évènements spéciaux qui pourraient avoir 
influencé votre état dans la journée, vous pouvez les écrire en bas de la page des 




Consignes pour remplir le journal 
d’alimentation et la liste des médicaments 
 
 Indiquez l’heure de vos repas et de vos collations. 
 
 Donner une description complète de votre alimentation. 
 
 Soyez le plus précis possible. 
Par exemple : 
Produits céréaliers, 
Légumes et fruits, 
Viandes ou substituts,  
Huiles et matières grasses,  
Lait ou substituts,  
Breuvages et produits caffeiné ou alcool,  
Autre 
 
 Indiquez l’heure de la prise des médicaments ainsi qu’une liste de ces 
médicaments et leur dosage. 
 
 Si vous fumez, indiquez les heures auxquelles vous avez fumé et le nombre 
de cigarettes (ou cigares et/ou pipes). 
Exemple : 
Heure: Description d'alimentation 
Déjeuner:   1 pain pita au blé entier, 1 petit morceau de fromage pour garnir 
 9h00  Demi tasse thé avec une demi tasse de lait 1% 
    
    
Collation:  1 banane, 10 amandes sans sel 
 10h30   
    
Heure: Liste de médicaments (dosage) 
9h00 Advair (100mcg), Asaphen ec 80mg 
  
   
   
 Heure: Nombre de cigarettes (ou cigares et/ou pipes) fumés 











Durant la semaine de suivi, nous vous demandons de répondre 3 fois par jour à 
5 questions qui correspondent à des sentiments que vous éprouvez sur vous-
même. Pour chacune, nous vous demandons de faire un trait vertical entre les 
bornes « pas du tout » et « tout à fait » sur la ligne horizontale en fonction de 
l’intensité choisie. Il s’agit d’échelle visuelle analogique. Le principe de réponse à 
ces échelles vous est présenté ci-dessous. Ceci n’est qu’un exemple des 
multiples réponses possibles. 
 
Pas du tout  Tout à fait 
 
Pas du tout  Tout à fait 
 
Pas du tout  Tout à fait 
 
Pas du tout  Tout à fait 
 
 

















 Vous devez porter un moniteur au poignet __________ de façon continue 
(autant que possible), 24 heures par jour, incluant la période de sommeil. 
 
 Si vous faites des activités durant lesquelles vous ne pouvez pas garder le 
moniteur (ex : bain/douche, laver la vaisselle, natation), écrivez dans votre 
agenda les heures durant lesquelles vous avez retiré le moniteur en 
indiquant la raison. 
 
 Les moniteurs sont résistants à l’eau, mais pas imperméables. Ne pas 
les plonger dans l’eau et veiller à les protéger autant que possible de 
la pluie. 
 
 Les moniteurs sont sensibles aux chocs : évitez autant que possible de les 
cogner ou de les échapper. 
 
 Ne jamais essayer d’ouvrir les moniteurs ou de démonter une de leurs 
pièces. 
 
 Veuillez indiquer avec le plus de précision possible vos heures de lever et 
de coucher dans les agendas de sommeil. Cette information nous aidera à 
interpréter vos données. 
 
 Veuillez presser le marqueur sur l’actiwatch pour préciser quand vous 


















Heure :_________     Questionnaire du Matin 1 
98 
 
Heure: Description d'alimentation 
Déjeuner:   
    
    
Collation:   
    
Heure: Liste de médicaments (dosage) 
   
   
 Heure: Nombre de cigarettes (ou cigares et/ou pipes) fumés 
   
1. A quelle heure vous êtes vous couché(e) hier soir? ____h____ 
2. Combien de temps avez-vous pris pour vous endormir? 
 moins de 15 minutes    15 à 30 minutes    30 à 60 minutes    1 heure ou plus 
3. Vous êtes-vous réveillé(e) durant la nuit?  Non    Oui 
Si oui, combien de fois ?__ Qu’est-ce qui vous a réveillé(e)?___________________ 
4. A quelle heure vous êtes-vous réveillé(e) pour de bon ce matin? ____h____ 
5. A quelle heure vous êtes-vous levé(e) ce matin ? ____h____ 
6. Sur une échelle de 1 (très mal dormi) à 5 (très bien dormi), entourez le chiffre 
correspondant le mieux à la qualité de votre sommeil: 
1 2 3 4 5 
Très mal dormi    Très bien dormi 
7. Sur une échelle de 1 (très fatigué(e), endormi(e), faible) à 5 (très en forme, 
éveillé(e), énergique), entourez le chiffre correspondant à votre forme au levé : 
1 2 3 4 5 
Très fatigué(e)    Très en forme 
Veuillez répondre à ces questions en mettant un trait vertical entre les bornes « pas du 
tout » et « tout à fait » 
Je suis heureux(se) 
Pas du tout  Tout à fait 
 
J’ai des crises de larmes ou me sens comme si j’allais éclater en sanglots 
Pas du tout  Tout à fait 
 
Je sens que les gens ne m’aiment pas 
Pas du tout  Tout à fait 
 
Je parle moins que d’habitude 
Pas du tout  Tout à fait 
 
Je suis incapable de me détendre 
Pas du tout  Tout à fait 
  
Veuillez mettre un trait au centre de la ligne ci-dessous  
   
Heure :_________      Questionnaire du Midi 1 
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Heure: Description d'alimentation 
Dîner:   
    
    
    
Collation:   
    
Heure: Liste de médicaments (dosage) 
    
   
 Heure: Nombre de cigarettes (ou cigares et/ou pipes) fumés 
   
Veuillez répondre à ces questions en mettant un trait vertical entre les bornes « pas du 
tout » et « tout à fait » 
Je suis heureux(se) 
Pas du tout  Tout à fait 
 
Je parle moins que d’habitude 
Pas du tout  Tout à fait 
 
Je sens que les gens ne m’aiment pas 
Pas du tout  Tout à fait 
 
J’ai des crises de larmes ou me sens comme si j’allais éclater en sanglots 
Pas du tout  Tout à fait 
 
Je suis incapable de me détendre 
Pas du tout  Tout à fait 
   
Veuillez mettre un trait au centre de la ligne ci-dessous  








Heure :_________      Questionnaire du Soir 1 
100 
 
Heure: Description d'alimentation 
Souper:   
    
    
    
Collation:   
    
Heure: Liste de médicaments (dosage) 
   
   
 Heure: Nombre de cigarettes (ou cigares et/ou pipes) fumés 
   
1. Avez-vous fait une sieste aujourd’hui? __ Non __ Oui 
Si oui, de quelle heure à quelle heure? De __________ à ____________ 
Avez-vous dormi? _______ 
2. Avez-vous fait des activités physiques aujourd’hui? __ Non __ Oui 
Si oui: Quoi et à quelle heure: _______________________________________ 
3. Avez-vous enlevé le moniteur d’activité ? __ Non __ Oui 
Si oui, de quelle heure à quelle heure? De __________ à ____________ 
Pourquoi ? ______________________________________________________ 
Veuillez répondre à ces questions en mettant un trait vertical entre les bornes « pas du 
tout » et « tout à fait » 
Je suis incapable de me détendre 
Pas du tout  Tout à fait 
 
Je suis heureux(se) 
Pas du tout  Tout à fait 
 
J’ai des crises de larmes ou me sens comme si j’allais éclater en sanglots 
Pas du tout  Tout à fait 
 
Je parle moins que d’habitude 
Pas du tout  Tout à fait 
 
Je sens que les gens ne m’aiment pas 
Pas du tout  Tout à fait 
   
Veuillez mettre un trait au centre de la ligne ci-dessous  
   







Heure :_________     Questionnaire du Matin 2 
101 
 
Heure: Description d'alimentation 
Déjeuner:   
    
    
Collation:   
    
Heure: Liste de médicaments (dosage) 
   
   
 Heure: Nombre de cigarettes (ou cigares et/ou pipes) fumés 
  
1. A quelle heure vous êtes vous couché(e) hier soir? ____h____ 
2. Combien de temps avez-vous pris pour vous endormir? 
    moins de 15 minutes  15 à 30 minutes  30 à 60 minutes  1 heure ou plus 
3. Vous êtes-vous réveillé(e) durant la nuit?  Non    Oui 
Si oui, combien de fois ?__  Qu’est-ce qui vous a réveillé(e)?___________________ 
4. A quelle heure vous êtes-vous réveillé(e) pour de bon ce matin? ____h____ 
5. A quelle heure vous êtes-vous levé(e) ce matin ? ____h____ 
6. Sur une échelle de 1 (très mal dormi) à 5 (très bien dormi), entourez le chiffre 
correspondant le mieux à la qualité de votre sommeil: 
1 2 3 4 5 
Très mal dormi    Très bien dormi 
7. Sur une échelle de 1 (très fatigué(e), endormi(e), faible) à 5 (très en forme, 
éveillé(e), énergique), entourez le chiffre correspondent à votre forme au levé : 
1 2 3 4 5 
Très fatigué(e)    Très en forme 
Veuillez répondre à ces questions en mettant un trait vertical entre les bornes « pas du 
tout » et « tout à fait » 
Je suis heureux(se) 
Pas du tout  Tout à fait 
 
Je suis incapable de me détendre 
Pas du tout  Tout à fait 
 
Je parle moins que d’habitude 
Pas du tout  Tout à fait 
 
J’ai des crises de larmes ou me sens comme si j’allais éclater en sanglots 
Pas du tout  Tout à fait 
 
Je sens que les gens ne m’aiment pas 
Pas du tout  Tout à fait 
  
Veuillez mettre un trait au centre de la ligne ci-dessous  
   




Heure: Description d'alimentation 
Dîner:   
    
    
    
Collation:   
    
Heure: Liste de médicaments (dosage) 
   
   
 Heure: Nombre de cigarettes (ou cigares et/ou pipes) fumés 
   
Veuillez répondre à ces questions en mettant un trait vertical entre les bornes « pas du 
tout » et « tout à fait » 
J’ai des crises de larmes ou me sens comme si j’allais éclater en sanglots 
Pas du tout  Tout à fait 
 
Je sens que les gens ne m’aiment pas 
Pas du tout  Tout à fait 
 
Je parle moins que d’habitude 
Pas du tout  Tout à fait 
 
Je suis heureux(se) 
Pas du tout  Tout à fait 
 
Je suis incapable de me détendre 
Pas du tout  Tout à fait 
   
Veuillez mettre un trait au centre de la ligne ci-dessous  
   
 
Heure :_________     Questionnaire du Soir 2 
103 
 
Heure: Description d'alimentation 
Souper:   
    
    
    
Collation:   
    
Heure: Liste de médicaments (dosage) 
   
   
 Heure: Nombre de cigarettes (ou cigares et/ou pipes) fumés 
   
1. Avez-vous fait une sieste aujourd’hui? __ Non __ Oui 
Si oui, de quelle heure à quelle heure? De __________ à ____________ 
Avez-vous dormi? _______ 
2. Avez-vous fait des activités physiques aujourd’hui? __ Non __ Oui 
Si oui: Quoi et à quelle heure: _______________________________________ 
3. Avez-vous enlevé le moniteur d’activité ? __ Non __ Oui 
Si oui, de quelle heure à quelle heure? De __________ à ____________ 
Pourquoi ? ______________________________________________________ 
Veuillez répondre à ces questions en mettant un trait vertical entre les bornes « pas du 
tout » et « tout à fait » 
J’ai des crises de larmes ou me sens comme si j’allais éclater en sanglots 
Pas du tout  Tout à fait 
 
Je sens que les gens ne m’aiment pas 
Pas du tout  Tout à fait 
 
Je parle moins que d’habitude 
Pas du tout  Tout à fait 
 
Je suis heureux(se) 
Pas du tout  Tout à fait 
 
Je suis incapable de me détendre 
Pas du tout  Tout à fait 
   
Veuillez mettre un trait au centre de la ligne ci-dessous  
   







Heure :_________     Questionnaire du Matin 3 
104 
 
Heure: Description d'alimentation 
Déjeuner:   
    
    
Collation:   
    
Heure: Liste de médicaments (dosage) 
   
   
 Heure: Nombre de cigarettes (ou cigares et/ou pipes) fumés 
  1. A quelle heure vous êtes vous couché(e) hier soir? ____h____ 
2. Combien de temps avez-vous pris pour vous endormir? 
    moins de 15 minutes  15 à 30 minutes  30 à 60 minutes  1 heure ou plus 
3. Vous êtes-vous réveillé(e) durant la nuit?  Non    Oui 
Si oui, combien de fois ?__  Qu’est-ce qui vous a réveillé(e)?___________________ 
4. A quelle heure vous êtes-vous reveillé(e) pour de bon ce matin? ____h____ 
5. A quelle heure vous êtes-vous levé(e) ce matin ? ____h____ 
6. Sur une échelle de 1 (très mal dormi) à 5 (très bien dormi), entourez le chiffre 
correspondant le mieux à la qualité de votre sommeil: 
1 2 3 4 5 
Très mal dormi    Très bien dormi 
7. Sur une échelle de 1 (très fatigué(e), endormi(e), faible) à 5 (très en forme, 
éveillé(e), énergique), entourez le chiffre correspondent à votre forme au levé : 
1 2 3 4 5 
Très fatigué(e)    Très en forme 
Veuillez répondre à ces questions en mettant un trait vertical entre les bornes « pas du 
tout » et « tout à fait » 
Je suis heureux(se) 
Pas du tout  Tout à fait 
 
Je suis incapable de me détendre 
Pas du tout  Tout à fait 
 
Je sens que les gens ne m’aiment pas 
Pas du tout  Tout à fait 
 
J’ai des crises de larmes ou me sens comme si j’allais éclater en sanglots 
Pas du tout  Tout à fait 
 
Je parle moins que d’habitude 
Pas du tout  Tout à fait 
   
Veuillez mettre un trait au centre de la ligne ci-dessous  
   
Heure :_________      Questionnaire du Midi 3 
105 
 
Heure: Description d'alimentation 
Dîner:   
    
    
    
Collation:   
    
Heure: Liste de médicaments (dosage) 
    
   
 Heure: Nombre de cigarettes (ou cigares et/ou pipes) fumés 
   
Veuillez répondre à ces questions en mettant un trait vertical entre les bornes « pas du 
tout » et « tout à fait » 
Je suis heureux(se) 
Pas du tout  Tout à fait 
 
Je sens que les gens ne m’aiment pas 
Pas du tout  Tout à fait 
 
J’ai des crises de larmes ou me sens comme si j’allais éclater en sanglots 
Pas du tout  Tout à fait 
 
Je parle moins que d’habitude 
Pas du tout  Tout à fait 
 
Je suis incapable de me détendre 
Pas du tout  Tout à fait 
   
Veuillez mettre un trait au centre de la ligne ci-dessous  
   
 
Heure :_________      Questionnaire du Soir 3 
106 
 
Heure: Description d'alimentation 
Souper:   
    
    
    
Collation:   
    
Heure: Liste de médicaments (dosage) 
   
   
 Heure: Nombre de cigarettes (ou cigares et/ou pipes) fumés 
  1. Avez-vous fait une sieste aujourd’hui? __ Non __ Oui 
Si oui, de quelle heure à quelle heure? De __________ à ____________ 
Avez-vous dormi? _______ 
2. Avez-vous fait des activités physiques aujourd’hui? __ Non __ Oui 
Si oui: Quoi et à quelle heure: _______________________________________ 
3. Avez-vous enlevé le moniteur d’activité ? __ Non __ Oui 
Si oui, de quelle heure à quelle heure? De __________ à ____________ 
Pourquoi ? ______________________________________________________ 
Veuillez répondre à ces questions en mettant un trait vertical entre les bornes « pas du 
tout » et « tout à fait » 
Je sens que les gens ne m’aiment pas 
Pas du tout  Tout à fait 
 
Je parle moins que d’habitude 
Pas du tout  Tout à fait 
 
J’ai des crises de larmes ou me sens comme si j’allais éclater en sanglots 
Pas du tout  Tout à fait 
 
Je suis incapable de me détendre 
Pas du tout  Tout à fait 
 
Je suis heureux(se) 
Pas du tout  Tout à fait 
   
Veuillez mettre un trait au centre de la ligne ci-dessous  
   







Heure :_________     Questionnaire du Matin 4 
107 
 
Heure: Description d'alimentation 
Déjeuner:   
    
    
Collation:   
    
Heure: Liste de medicaments (dosage) 
   
   
 Heure: Nombre de cigarettes (ou cigares et/ou pipes) fumés 
  1. A quelle heure vous êtes vous couché(e) hier soir? ____h____ 
2. Combien de temps avez-vous pris pour vous endormir? 
    moins de 15 minutes  15 à 30 minutes  30 à 60 minutes  1 heure ou plus 
3. Vous êtes-vous réveillé(e) durant la nuit?  Non    Oui 
Si oui, combien de fois ?__  Qu’est-ce qui vous a réveillé(e)?___________________ 
4. A quelle heure vous êtes-vous reveillé(e) pour de bon ce matin? ____h____ 
5. A quelle heure vous êtes-vous levé(e) ce matin ? ____h____ 
6. Sur une échelle de 1 (très mal dormi) à 5 (très bien dormi), entourez le chiffre 
correspondant le mieux à la qualité de votre sommeil: 
1 2 3 4 5 
Très mal dormi    Très bien dormi 
7. Sur une échelle de 1 (très fatigué(e), endormi(e), faible) à 5 (très en forme, 
éveillé(e), énergique), entourez le chiffre correspondent à votre forme au levé : 
1 2 3 4 5 
Très fatigué(e)    Très en forme 
Veuillez répondre à ces questions en mettant un trait vertical entre les bornes « pas du 
tout » et « tout à fait » 
Je sens que les gens ne m’aiment pas 
Pas du tout  Tout à fait 
 
Je parle moins que d’habitude 
Pas du tout  Tout à fait 
 
J’ai des crises de larmes ou me sens comme si j’allais éclater en sanglots 
Pas du tout  Tout à fait 
 
Je suis incapable de me détendre  
Pas du tout  Tout à fait 
 
Je suis heureux(se) 
Pas du tout  Tout à fait 
   
Veuillez mettre un trait au centre de la ligne ci-dessous  
   
Heure :_________      Questionnaire du Midi 4 
108 
 
Heure: Description d'alimentation 
Dîner:   
    
    
    
Collation:   
    
Heure: Liste de médicaments (dosage) 
   
   
 Heure: Nombre de cigarettes (ou cigares et/ou pipes) fumés 
   
Veuillez répondre à ces questions en mettant un trait vertical entre les bornes « pas du 
tout » et « tout à fait » 
Je suis heureux(se) 
Pas du tout  Tout à fait 
 
Je sens que les gens ne m’aiment pas 
Pas du tout  Tout à fait 
 
J’ai des crises de larmes ou me sens comme si j’allais éclater en sanglots 
Pas du tout  Tout à fait 
 
Je suis incapable de me détendre 
Pas du tout  Tout à fait 
 
Je parle moins que d’habitude 
Pas du tout  Tout à fait 
   
Veuillez mettre un trait au centre de la ligne ci-dessous  
   
 
Heure :_________      Questionnaire du Soir 4 
109 
 
Heure: Description d'alimentation 
Souper:   
    
    
    
Collation:   
    
Heure: Liste de médicaments (dosage) 
   
   
 Heure: Nombre de cigarettes (ou cigares et/ou pipes) fumés 
  1. Avez-vous fait une sieste aujourd’hui? __ Non __ Oui 
Si oui, de quelle heure à quelle heure? De __________ à ____________ 
Avez-vous dormi? _______ 
2. Avez-vous fait des activités physiques aujourd’hui? __ Non __ Oui 
Si oui: Quoi et à quelle heure: _______________________________________ 
3. Avez-vous enlevé le moniteur d’activité ? __ Non __ Oui 
Si oui, de quelle heure à quelle heure? De __________ à ____________ 
Pourquoi ? ______________________________________________________ 
Veuillez répondre à ces questions en mettant un trait vertical entre les bornes « pas du 
tout » et « tout à fait » 
Je suis incapable de me détendre 
Pas du tout  Tout à fait 
 
Je suis heureux(se) 
Pas du tout  Tout à fait 
 
Je sens que les gens ne m’aiment pas 
Pas du tout  Tout à fait 
 
Je parle moins que d’habitude 
Pas du tout  Tout à fait 
 
J’ai des crises de larmes ou me sens comme si j’allais éclater en sanglots 
Pas du tout  Tout à fait 
   
Veuillez mettre un trait au centre de la ligne ci-dessous  
   






Heure :_________     Questionnaire du Matin 5 
110 
 
Heure: Description d'alimentation 
Déjeuner:   
 
  
   
Collation:   
    
Heure: Liste de médicaments (dosage) 
    
 
  Heure: Nombre de cigarettes (ou cigares et/ou pipes) fumés 
  1. A quelle heure vous êtes vous couché(e) hier soir? ____h____ 
2. Combien de temps avez-vous pris pour vous endormir? 
    moins de 15 minutes  15 à 30 minutes  30 à 60 minutes  1 heure ou plus  
3. Vous êtes-vous réveillé(e) durant la nuit?  Non    Oui 
Si oui, combien de fois ?__  Qu’est-ce qui vous a réveillé(e)?___________________ 
4. A quelle heure vous êtes-vous reveillé(e) pour de bon ce matin? ____h____ 
5. A quelle heure vous êtes-vous levé(e) ce matin ? ____h____ 
6. Sur une échelle de 1 (très mal dormi) à 5 (très bien dormi), entourez le chiffre 
correspondant le mieux à la qualité de votre sommeil: 
1 2 3 4 5 
Très mal dormi    Très bien dormi 
7. Sur une échelle de 1 (très fatigué(e), endormi(e), faible) à 5 (très en forme, 
éveillé(e), énergique), entourez le chiffre correspondent à votre forme au levé : 
1 2 3 4 5 
Très fatigué(e)    Très en forme 
Veuillez répondre à ces questions en mettant un trait vertical entre les bornes « pas du 
tout » et « tout à fait » 
Je suis heureux(se) 
Pas du tout  Tout à fait 
 
J’ai des crises de larmes ou me sens comme si j’allais éclater en sanglots 
Pas du tout  Tout à fait 
 
Je parle moins que d’habitude 
Pas du tout  Tout à fait 
 
Je suis incapable de me détendre 
Pas du tout  Tout à fait 
 
Je sens que les gens ne m’aiment pas 
Pas du tout  Tout à fait 
   
Veuillez mettez un trait au centre de la ligne ci-dessous  
   
Heure :_________      Questionnaire du Midi 5 
111 
 
Heure: Description d'alimentation 
Dîner:   
    
    
    
Collation:   
    
Heure: Liste de médicaments (dosage) 
   
   
 Heure: Nombre de cigarettes (ou cigares et/ou pipes) fumés 
   
Veuillez répondre à ces questions en mettant un trait vertical entre les bornes « pas du 
tout » et « tout à fait » 
Je sens que les gens ne m’aiment pas 
Pas du tout  Tout à fait 
 
Je suis heureux(se) 
Pas du tout  Tout à fait 
 
Je suis incapable de me détendre 
Pas du tout  Tout à fait 
 
J’ai des crises de larmes ou me sens comme si j’allais éclater en sanglots 
Pas du tout  Tout à fait 
 
Je parle moins que d’habitude 
Pas du tout  Tout à fait 
   
Veuillez mettre un trait au centre de la ligne ci-dessous  
   
 
Heure :_________      Questionnaire du Soir 5 
112 
 
Heure: Description d'alimentation 
Souper:   
    
    
    
Collation:   
    
Heure: Liste de médicaments (dosage) 
   
   
 Heure: Nombre de cigarettes (ou cigares et/ou pipes) fumés 
  1. Avez-vous fait une sieste aujourd’hui? __ Non __ Oui 
Si oui, de quelle heure à quelle heure? De __________ à ____________ 
Avez-vous dormi? _______ 
2. Avez-vous fait des activités physiques aujourd’hui? __ Non __ Oui 
Si oui: Quoi et à quelle heure: _______________________________________ 
3. Avez-vous enlevé le moniteur d’activité ? __ Non __ Oui 
Si oui, de quelle heure à quelle heure? De __________ à ____________ 
Pourquoi ? ______________________________________________________ 
Veuillez répondre à ces questions en mettant un trait vertical entre les bornes 
« pas du tout » et « tout à fait » 
Je suis heureux(se) 
Pas du tout  Tout à fait 
 
Je sens que les gens ne m’aiment pas 
Pas du tout  Tout à fait 
 
Je suis incapable de me détendre 
Pas du tout  Tout à fait 
 
J’ai des crises de larmes ou me sens comme si j’allais éclater en sanglots 
Pas du tout  Tout à fait 
 
Je parle moins que d’habitude 
Pas du tout  Tout à fait 
   
Veuillez mettre un trait au centre de la ligne ci-dessous  
   







Heure :_________     Questionnaire du Matin 6 
113 
 
Heure: Description d'alimentation 
Déjeuner:   
    
    
Collation:   
    
Heure: Liste de médicaments (dosage) 
   
   
 Heure: Nombre de cigarettes (ou cigares et/ou pipes) fumés 
  1. A quelle heure vous êtes vous couché(e) hier soir? ____h____ 
2. Combien de temps avez-vous pris pour vous endormir? 
    moins de 15 minutes  15 à 30 minutes  30 à 60 minutes  1 heure ou plus  
3. Vous êtes-vous réveillé(e) durant la nuit?  Non    Oui 
Si oui, combien de fois ?__  Qu’est-ce qui vous a réveillé(e)?___________________ 
4. A quelle heure vous êtes-vous reveillé(e) pour de bon ce matin? ____h____ 
5. A quelle heure vous êtes-vous levé(e) ce matin ? ____h____ 
6. Sur une échelle de 1 (très mal dormi) à 5 (très bien dormi), entourez le chiffre 
correspondant le mieux à la qualité de votre sommeil: 
1 2 3 4 5 
Très mal dormi    Très bien dormi 
7. Sur une échelle de 1 (très fatigué(e), endormi(e), faible) à 5 (très en forme, 
éveillé(e), énergique), entourez le chiffre correspondent à votre forme au levé : 
1 2 3 4 5 
Très fatigué(e)    Très en forme 
Veuillez répondre à ces questions en mettant un trait vertical entre les bornes 
« pas du tout » et « tout à fait » 
J’ai des crises de larmes ou me sens comme si j’allais éclater en sanglots 
Pas du tout  Tout à fait 
 
Je sens que les gens ne m’aiment pas 
Pas du tout  Tout à fait 
 
Je suis incapable de me détendre 
Pas du tout  Tout à fait 
 
Je suis heureux(se) 
Pas du tout  Tout à fait 
 
Je parle moins que d’habitude 
Pas du tout  Tout à fait 
   
Veuillez mettez un trait au centre de la ligne ci-dessous  
   
Heure :_________      Questionnaire du Midi 6 
114 
 
Heure: Description d'alimentation 
Dîner:   
    
    
    
Collation:   
    
Heure: Liste de médicaments (dosage) 
   
   
 Heure: Nombre de cigarettes (ou cigares et/ou pipes) fumés 
   
Veuillez répondre à ces questions en mettant un trait vertical entre les bornes 
« pas du tout » et « tout à fait » 
Je parle moins que d’habitude 
Pas du tout  Tout à fait 
 
J’ai des crises de larmes ou me sens comme si j’allais éclater en sanglots 
Pas du tout  Tout à fait 
 
Je suis incapable de me détendre 
Pas du tout  Tout à fait 
 
Je suis heureux(se) 
Pas du tout  Tout à fait 
 
Je sens que les gens ne m’aiment pas 
Pas du tout  Tout à fait 
   
Veuillez mettre un trait au centre de la ligne ci-dessous  
   
 
Heure :_________      Questionnaire du Soir 6 
115 
 
Heure: Description d'alimentation 
Souper:   
    
    
    
Collation:   
    
Heure: Liste de médicaments (dosage) 
   
   
 Heure: Nombre de cigarettes (ou cigares et/ou pipes) fumés 
  1. Avez-vous fait une sieste aujourd’hui? __ Non __ Oui 
Si oui, de quelle heure à quelle heure? De __________ à ____________ 
Avez-vous dormi? _______ 
2. Avez-vous fait des activités physiques aujourd’hui? __ Non __ Oui 
Si oui: Quoi et à quelle heure: _______________________________________ 
3. Avez-vous enlevé le moniteur d’activité ? __ Non __ Oui 
Si oui, de quelle heure à quelle heure? De __________ à ____________ 
Pourquoi ? ______________________________________________________ 
Veuillez répondre à ces questions en mettant un trait vertical entre les bornes 
« pas du tout » et « tout à fait » 
Je sens que les gens ne m’aiment pas 
Pas du tout  Tout à fait 
 
J’ai des crises de larmes ou me sens comme si j’allais éclater en sanglots 
Pas du tout  Tout à fait 
 
Je suis heureux(se) 
Pas du tout  Tout à fait 
 
Je suis incapable de me détendre 
Pas du tout  Tout à fait 
 
Je parle moins que d’habitude 
Pas du tout  Tout à fait 
   
Veuillez mettre un trait au centre de la ligne ci-dessous  
   







Heure :_________     Questionnaire du Matin 7 
116 
 
Heure: Description d'alimentation 
Déjeuner:   
    
    
Collation:   
    
    
Heure: Liste de médicaments (dosage) 
   
   
 Heure: Nombre de cigarettes (ou cigares et/ou pipes) fumés 
  1. A quelle heure vous êtes vous couché(e) hier soir? ____h____ 
2. Combien de temps avez-vous pris pour vous endormir? 
    moins de 15 minutes  15 à 30 minutes  30 à 60 minutes  1 heure ou plus  
3. Vous êtes-vous réveillé(e) durant la nuit?  Non    Oui 
Si oui, combien de fois ?__  Qu’est-ce qui vous a réveillé(e)?___________________ 
4. A quelle heure vous êtes-vous reveillé(e) pour de bon ce matin? ____h____ 
5. A quelle heure vous êtes-vous levé(e) ce matin ? ____h____ 
6. Sur une échelle de 1 (très mal dormi) à 5 (très bien dormi), entourez le chiffre 
correspondant le mieux à la qualité de votre sommeil: 
1 2 3 4 5 
Très mal dormi    Très bien dormi 
7. Sur une échelle de 1 (très fatigué(e), endormi(e), faible) à 5 (très en forme, 
éveillé(e), énergique), entourez le chiffre correspondent à votre forme au levé : 
1 2 3 4 5 
Très fatigué(e)    Très en forme 
Veuillez répondre à ces questions en mettant un trait vertical entre les bornes 
« pas du tout » et « tout à fait » 
Je suis incapable de me détendre 
Pas du tout  Tout à fait 
Je parle moins que d’habitude 
Pas du tout  Tout à fait 
Je sens que les gens ne m’aiment pas 
Pas du tout  Tout à fait 
Je suis heureux(se) 
Pas du tout  Tout à fait 
J’ai des crises de larmes ou me sens comme si j’allais éclater en sanglots 
Pas du tout  Tout à fait 
Veuillez mettre un trait au centre de la ligne ci-dessous  
   
Heure :_________      Questionnaire du Midi 7 
117 
 
Heure: Description d'alimentation 
Dîner:   
    
    
    
Collation:   
    
Heure: Liste de médicaments (dosage) 
   
   
 Heure: Nombre de cigarettes (ou cigares et/ou pipes) fumés 
   
Veuillez répondre à ces questions en mettant un trait vertical entre les bornes 
« pas du tout » et « tout à fait » 
Je suis incapable de me détendre 
Pas du tout  Tout à fait 
 
Je suis heureux(se) 
Pas du tout  Tout à fait 
 
J’ai des crises de larmes ou me sens comme si j’allais éclater en sanglots 
Pas du tout  Tout à fait 
 
Je parle moins que d’habitude 
Pas du tout  Tout à fait 
 
Je sens que les gens ne m’aiment pas 
Pas du tout  Tout à fait 
   
Veuillez mettre un trait au centre de la ligne ci-dessous  
   
Heure :_________      Questionnaire du Soir 7 
118 
 
Heure: Description d'alimentation 
Souper:   
    
    
    
Collation:   
    
Heure: Liste de médicaments (dosage) 
   
   
 Heure: Nombre de cigarettes (ou cigares et/ou pipes) fumés 
  1. Avez-vous fait une sieste aujourd’hui? __ Non __ Oui 
Si oui, de quelle heure à quelle heure? De __________ à ____________ 
Avez-vous dormi? _______ 
2. Avez-vous fait des activités physiques aujourd’hui? __ Non __ Oui 
Si oui: Quoi et à quelle heure: _______________________________________ 
3. Avez-vous enlevé le moniteur d’activité ? __ Non __ Oui 
Si oui, de quelle heure à quelle heure? De __________ à ____________ 
Pourquoi ? ______________________________________________________ 
Veuillez répondre à ces questions en mettant un trait vertical entre les bornes 
« pas du tout » et « tout à fait » 
Je parle moins que d’habitude 
Pas du tout  Tout à fait 
 
Je sens que les gens ne m’aiment pas 
Pas du tout  Tout à fait 
 
Je suis incapable de me détendre 
Pas du tout  Tout à fait 
 
Je suis heureux(se) 
Pas du tout  Tout à fait 
 
J’ai des crises de larmes ou me sens comme si j’allais éclater en sanglots 
Pas du tout  Tout à fait 
   
Veuillez mettre un trait au centre de la ligne ci-dessous  
   






Heure :_________     Questionnaire du Matin 8 
119 
 
Heure: Description d'alimentation 
Déjeuner:   
    
    
Collation:   
    
    
Heure: Liste de médicaments (dosage) 
   
   
 Heure: Nombre de cigarettes (ou cigares et/ou pipes) fumés 
  1. A quelle heure vous êtes vous couché(e) hier soir? ____h____ 
2. Combien de temps avez-vous pris pour vous endormir? 
    moins de 15 minutes  15 à 30 minutes  30 à 60 minutes  1 heure ou plus  
3. Vous êtes-vous réveillé(e) durant la nuit?  Non    Oui 
Si oui, combien de fois ?__  Qu’est-ce qui vous a réveillé(e)?___________________ 
4. A quelle heure vous êtes-vous reveillé(e) pour de bon ce matin? ____h____ 
5. A quelle heure vous êtes-vous levé(e) ce matin ? ____h____ 
6. Sur une échelle de 1 (très mal dormi) à 5 (très bien dormi), entourez le chiffre 
correspondant le mieux à la qualité de votre sommeil: 
1 2 3 4 5 
Très mal dormi    Très bien dormi 
7. Sur une échelle de 1 (très fatigué(e), endormi(e), faible) à 5 (très en forme, 
éveillé(e), énergique), entourez le chiffre correspondent à votre forme au levé : 
1 2 3 4 5 
Très fatigué(e)    Très en forme 
Veuillez répondre à ces questions en mettant un trait vertical entre les bornes 
« pas du tout » et « tout à fait » 
J’ai des crises de larmes ou me sens comme si j’allais éclater en sanglots 
Pas du tout  Tout à fait 
Je suis heureux(se) 
Pas du tout  Tout à fait 
Je suis incapable de me détendre 
Pas du tout  Tout à fait 
Je parle moins que d’habitude 
Pas du tout  Tout à fait 
Je sens que les gens ne m’aiment pas 
Pas du tout  Tout à fait 
Veuillez mettre un trait au centre de la ligne ci-dessous  
   
Heure :_________      Questionnaire du Midi 8 
120 
 
Heure: Description d'alimentation 
Dîner:   
    
    
    
Collation:   
    
Heure: Liste de médicaments (dosage) 
   
   
 Heure: Nombre de cigarettes (ou cigares et/ou pipes) fumés 
   
Veuillez répondre à ces questions en mettant un trait vertical entre les bornes 
« pas du tout » et « tout à fait » 
Je suis heureux(se) 
Pas du tout  Tout à fait 
 
Je parle moins que d’habitude 
Pas du tout  Tout à fait 
 
Je sens que les gens ne m’aiment pas  
Pas du tout  Tout à fait 
 
J’ai des crises de larmes ou me sens comme si j’allais éclater en sanglots  
Pas du tout  Tout à fait 
 
Je suis incapable de me détendre 
Pas du tout  Tout à fait 
   
Veuillez mettre un trait au centre de la ligne ci-dessous  
   
 
Heure :_________      Questionnaire du Soir 8 
121 
 
Heure: Description d'alimentation 
Souper:   
    
    
    
Collation:   
    
Heure: Liste de médicaments (dosage) 
   
   
 Heure: Nombre de cigarettes (ou cigares et/ou pipes) fumés 
  1. Avez-vous fait une sieste aujourd’hui? __ Non __ Oui 
Si oui, de quelle heure à quelle heure? De __________ à ____________ 
Avez-vous dormi? _______ 
2. Avez-vous fait des activités physiques aujourd’hui? __ Non __ Oui 
Si oui: Quoi et à quelle heure: _______________________________________ 
3. Avez-vous enlevé le moniteur d’activité ? __ Non __ Oui 
Si oui, de quelle heure à quelle heure? De __________ à ____________ 
Pourquoi ? ______________________________________________________ 
Veuillez répondre à ces questions en mettant un trait vertical entre les bornes 
« pas du tout » et « tout à fait » 
Je suis incapable de me détendre 
Pas du tout  Tout à fait 
 
Je suis heureux(se) 
Pas du tout  Tout à fait 
 
J’ai des crises de larmes ou me sens comme si j’allais éclater en sanglots 
Pas du tout  Tout à fait 
 
Je parle moins que d’habitude 
Pas du tout  Tout à fait 
 
Je sens que les gens ne m’aiment pas 
Pas du tout  Tout à fait 
   
Veuillez mettez un trait au centre de la ligne ci-dessous  
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